

1 Single-cell atlas of transcriptomic vulnerability 2 across multiple neurodegenerative and 3 neuropsychiatric diseases

4

5 **Authors**

6 Donghoon Lee^{†#1,2,3,4}, Mikaela Koutrouli^{#1,2,3,4,5}, Nicolas Y. Masse^{#1,2,3,4}, Gabriel E. Hoffman^{#1,2,3,4,6,7}, Seon
7 Kinrot^{1,2,3,4}, Xinyi Wang^{1,2,3,4}, Prashant N.M.^{1,2,3,4}, Milos Pjanic^{1,2,3,4}, Tereza Clarence^{1,2,3,4}, Fotios Tsetsos^{1,2,3,4,6},
8 Deepika Mathur^{1,2,3,4,6,7}, David Burstein^{1,2,3,4,6,7}, Karen Therrien^{1,2,3,4}, Aram Hong^{1,2,3,4}, Clara Casey^{1,2,3,4}, Zhiping
9 Shao^{1,2,3,4}, Marcela Alvia^{1,2,3,4}, Stathis Argyriou^{1,2,3,4}, Jennifer Monteiro Fortes^{1,2,3,4}, Pavel Katsel³, Pavan K.
10 Auluck⁸, Lisa L. Barnes^{9,10}, Stefano Marengo⁸, David A. Bennett^{9,10}, PsychAD Consortium¹¹, Lars Juhl Jensen⁵,
11 Kiran Girdhar^{1,2,3,4}, Georgios Voloudakis^{1,2,3,4,6,7,12}, Vahram Haroutunian^{2,3,7,13}, Jaroslav Bendl^{1,2,3,4}, John F.
12 Fullard^{#1,2,3,4}, Panos Roussos^{†#1,2,3,4,6,7}

13

14 **Affiliations**

15 1 Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
16 2 Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
17 3 Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
18 4 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY,
19 USA.
20 5 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of
21 Copenhagen, Copenhagen, Denmark.
22 6 Center for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx,
23 NY, USA.
24 7 Mental Illness Research, Education and Clinical Center VISN2, James J. Peters VA Medical Center, Bronx,
25 NY, USA.
26 8 Human Brain Collection Core, National Institute of Mental Health-Intramural Research Program, Bethesda,
27 MD, USA.
28 9 Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
29 10 Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
30 11 [PsychAD Consortium](#)
31 12 Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York,
32 NY, USA.
33 13 Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

34

35 # These authors contributed equally to this work.

36 † Corresponding author: donghoon.lee@mssm.edu; panagiotis.roussos@mssm.edu

37 **Abstract**

38 Neurodegenerative and neuropsychiatric diseases impose a significant societal and public health burden.
39 However, our understanding of the molecular mechanisms underlying these highly complex conditions remains
40 limited. To gain deeper insights into the etiology of different brain diseases, we used specimens from 1,494
41 unique donors to generate a population-scale single-cell transcriptomic atlas of the human dorsolateral
42 prefrontal cortex (DLPFC), comprising over 6.3 million individual nuclei. The cohort includes neurotypical
43 controls as well as donors affected by eight common and complex brain disorders: Alzheimer's disease (AD),
44 diffuse Lewy body disease (DLBD), vascular dementia (Vas), Parkinson's disease (PD), tauopathy,
45 frontotemporal dementia, schizophrenia, and bipolar disorder. We show that inter-individual variation accounts
46 for a substantial portion of gene expression variation in the DLPFC. By comparing transcriptomic variation
47 across diseases, we reveal universal signatures enriched in basic cellular functions such as mRNA splicing
48 and protein localization. After discounting these cross-disease signatures, we show strong genetic and
49 transcriptomic concordance among AD, DLBD, Vas, and PD, largely driven by alteration of synaptic signaling
50 functions in neurons. Furthermore, we characterize transcriptomic variation among different AD phenotypes
51 that were distinct from healthy aging. We uncover mitigating effects of interneurons and aggravating effects of
52 immune and vascular cells in AD dementia. Further exploring the effect of the neuropsychiatric symptoms
53 frequently accompanying AD, we identify a link to deep layer excitatory neurons. By constructing transcriptome
54 trajectories that capture AD progression, we show cell-type specific responses implicated in early and late
55 stages of AD. Our atlas provides an unprecedented perspective of the transcriptomic landscape in
56 neurodegenerative and neuropsychiatric diseases, shedding light on shared and distinct processes involving
57 the neuro-immune-vascular systems, and identifying potential targets for therapeutic intervention.

58 **Main**

59 The human brain is a highly complex organ composed of billions of functionally diverse cells. Under
60 pathogenic stress, cellular and molecular responses are often convoluted and contextual, so understanding
61 their dysfunction in disease is challenging. Recent work has begun to unravel the molecular changes that
62 occur at the single-cell level, which has been particularly helpful in understanding the vulnerability of specific
63 cell types in various disease contexts, as well as the complex interplay between different cell types. In
64 Alzheimer's disease (AD), it has been shown that a thorough exposition of cellular heterogeneity in the brain,
65 the coordinated interactions between neurons and glia, and the selective depletion of vulnerable inhibitory
66 neuronal subtypes are critical for understanding AD pathology^{1,2}.

67 Building a large-scale disease atlas at single-cell resolution creates an unprecedented opportunity to
68 understand molecular responses at the cellular level and estimate population-level variation in the brain
69 transcriptome. A large sample size provides the resolution needed to establish robust basal-level conditions
70 and to sufficiently capture the full spectrum of disease pathology. By leveraging cross-disease atlases, studies
71 have revealed shared and distinct patterns of gene-expression perturbations in major psychiatric diseases as
72 well as shared genetic factors leading to molecular convergence^{3,4}. As such, characterizing shared
73 transcriptomic vulnerabilities and pathophysiology together has significant implications for early treatment and
74 the development of effective therapeutics.

75 Here, we introduce the PsychAD cohort, which consists of 1,494 unique brain donors affected by various
76 neurodegenerative and neuropsychiatric diseases in addition to neurotypical controls. The resulting single-
77 nucleus RNA sequencing (snRNA-seq) dataset in the dorsolateral prefrontal cortex (DLPFC) of those donors,
78 comprising over 6.3 million nuclei representing 27 distinct subclasses of cells, is sufficiently-powered to identify
79 molecular signatures from multiple traits while accounting for individual variation. We utilize this dataset to
80 uncover shared transcriptomic vulnerability across these diseases and, in so doing, to better understand
81 specific transcriptional patterns and regulatory drivers underpinning each trait. By characterizing putative
82 disease-driving molecular changes across multiple traits, we differentiate shared and novel disease- and cell
83 type-specific associations. Concordance between heritability estimates and transcriptomic similarity identifies
84 shared genetic factors underlying cross-disorder traits. Deep phenotyping of AD trajectories using Tau
85 pathology and clinical dementia status suggests a potential link between immune and brain vasculature
86 dysfunctions. In summary, our study provides a rich and comprehensive resource for exploring the cellular and
87 molecular mechanisms of brain function and dysfunction across multiple neurodegenerative and
88 neuropsychiatric diseases.

89 **The PsychAD cohort represents diverse neurodegenerative and** 90 **neuropsychiatric diseases across the lifespan**

91 The PsychAD cohort comprises 1,494 unique brain donors (**Fig. 1a, Supplementary Table 1**). Brain tissue
92 specimens were obtained from three sources: 1,042 donors from Mount Sinai NIH Neurobiobank (MSSM), 300
93 from Human Brain Collection Core (HBCC), and 152 from Rush Alzheimer's Disease Center (RADC). The
94 cohort covers the whole lifespan of postnatal ages between 0 and 108, roughly equal numbers of males and
95 females, and represents a diverse range of disease phenotypes, including Alzheimer's disease (AD), diffuse
96 Lewy body disease (DLBD), vascular dementia (Vas), tauopathy (Tau), frontotemporal dementia (FTD),
97 Parkinson's disease (PD), schizophrenia (SCZ), and bipolar disorder (BD). The cohort covers a diverse genetic
98 background and over 30% of the donors were of non-European (EUR) ancestry.

99 We streamlined the unified processing of the data as well as the harmonization of clinical, and technical
100 metadata (**Fig. 1b, Supplementary Fig. 1a, Methods**). Frozen brain specimens were randomized and
101 processed in batches of 6. Equal numbers of nuclei from each sample were pooled together and each pool





102 was subjected to snRNA-seq twice to generate a technical replicate. Following quality control (**Supplementary**
103 **Figs. 1c-i**), the final data sets consisted of 6,320,459 nuclei. To characterize transcriptomic vulnerability across
104 multiple neuropsychiatric and neurodegenerative diseases, we organized the analysis into three tiers.

105 First, we focused on the cross-disorder analyses (**Fig. 1c**). We targeted six neurodegenerative diseases
106 (NDDs, including AD, DLBD, Vas, Tau, FTD, and PD) and two neuropsychiatric diseases (NPDs, including
107 SCZ and BD), using a subset of 1,160 donors with minimal comorbidity aged ≥ 17 . To estimate the sharing of
108 transcriptomic vulnerability, we compared donors affected with NDDs and NPDs against the baseline of 319
109 neurotypical controls.

110 The second-tier analysis focused on the stage of AD progression based on pathological and cognitive
111 impairment measures using a subset of 696 individuals (**Fig. 1d**). To uncover cell-type-specific roles in disease
112 onset and disease trajectory, we compared two characteristic neuropathological abnormalities of the AD brain:
113 the accumulation of amyloid- β ($A\beta$) plaques measured using CERAD plaque density score and tau-based
114 neurofibrillary tangle (NFT) pathology measured using Braak staging, along with cognitive impairment.

115 In the third tier, we surveyed neuropsychiatric symptoms (NPS) within 234 individuals affected by AD
116 pathology (**Fig. 1e, Supplementary Fig. 1b**). NPS are core features of AD and are common in patients with
117 dementia⁵. We broadly categorized NPS into three groups, (1) depression or mood-related, (2) weight loss or
118 psychomotor agitation (PMA), and (3) weight gain, insomnia, or suicidal ideation, based on co-occurrence
119 estimates, sharing molecular mechanisms that lead to increased prevalence with disease severity.

120




*54 donors with incomplete pathology or cognitive status omitted

122 **Fig. 1. Overview of the PsychAD cohort and study design. (a)** Breakdown of donors by tissue source,
123 number of diagnoses, genetic ancestry, distribution of age at death, sex, and % availability of genotype data.
124 **(b)** Data generation and analysis workflow. **(c)** A subset of the PsychAD cohort (n=1,160 donors) focused on
125 cross-disorder contrasts. This subset includes a group of neurotypical controls that were used to compare
126 against 8 neurodegenerative and neuropsychiatric disorders. UpSet plot describing available disease
127 phenotypes and number of unique donors by brain bank. **(d)** A subset of the PsychAD cohort (n=696 donors)
128 focused on AD phenotype contrasts. Comparison of different measures of AD severity, including neuritic
129 plaque density (CERAD), neurofibrillary tangle (NFT) pathology, and cognitive impairments. *n=54 donors with
130 incomplete pathology or cognitive status were omitted from the figure. **(e)** A subset of the PsychAD cohort
131 (n=234 donors) was used to characterize single-cell transcriptomic changes underlying NPS in AD. AFR:
132 African, AMR: Ad Mixed American, EAS: East Asian, SAS: South Asian, EUR: European, NPS:
133 Neuropsychiatric Symptom, PMA: Psychomotor Agitation, PMR: Psychomotor Retardation.

134 **Unified processing and hierarchical cellular taxonomy of the human** 135 **prefrontal cortex uncovers 27 distinct subclasses of cells**

136 To understand heterogeneous human cortical tissues in disease contexts, we require a cell type taxonomy
137 that is robust to aging, disease phenotypes, and various sampling and technical biases. Following unified
138 computational processing, quality controls, and batch normalization of snRNA-seq libraries representing 1,494
139 dissections, processed in duplicate (**Methods**), we annotated cell types of the human DLPFC using the cell
140 taxonomy of the primate DLPFC⁶ and human primary motor cortex⁷ as a baseline reference. The resulting
141 human DLPFC cellular taxonomy was organized using three levels of hierarchy, identifying 8 broad cell
142 classes, 27 subclasses, and 65 functionally distinct subtypes (**Fig. 2a, Supplementary Table 2**). Each level of
143 the annotation hierarchy represents a slice in the clustering dendrogram. At the top, the “class level” of the
144 annotation hierarchy defines 8 major cell types, including two broad neuronal cell types: glutamatergic
145 excitatory (EN) and GABAergic inhibitory neurons (IN), three glial: astrocytes (Astro), oligodendrocytes (Oligo),
146 and oligodendrocyte progenitor cells (OPC), and three non-neuronal cell types: immune cells (Immune), mural
147 and vascular cells (Mural), and endothelial cells (Endo). Subsequent levels of the annotation hierarchy,
148 subclasses and subtypes, were derived by iteratively re-clustering the subset of cells by gene matrix using a
149 new set of variable genes relevant to the particular cell type (see *iterative clustering* in **Methods**). The subclass
150 level distinguished the EN class into 10 subclasses and the IN class into 7 subclasses (**Supplementary Figs.**
151 **2c,d**). Different types of neurons, especially ENs, are organized into six horizontal layers (L1-L6) that are
152 distinct in both cytoarchitecture and function⁸. *In situ* spatial transcriptomics data was used to confirm that the
153 EN subclasses were spatially distinct and found in their respective neocortical layers (**Fig. 2b**). The EN
154 subclasses were denoted by their laminar organization (L2-6) and axon projection characteristics (IT: intra-
155 telencephalic, ET: extra-telencephalic, NP: near projecting, CT: corticothalamic, and L6B). IN subclasses were
156 determined using their characteristic marker genes (**Figs. 2c,d**); Ivy cells (IN_LAMP5_LHX6), neurogliaform
157 cells (IN_LAMP5_RELN), basket cells (IN_PVALB), chandelier cells (IN_PVALB_CHC), Martinotti and non-
158 Martinotti cells (IN_SST), VIP (IN_VIP), and homologs of mouse Sncg inhibitory neurons⁶ (IN_ADARB2).
159 Unlike laminar organization of EN, IN subclasses were distributed randomly throughout the gray matter, except
160 for IN_ADARB2, which was predominantly found in the superficial layer of the neocortex (**Supplementary Fig.**
161 **2e**). Some previously annotated rare inhibitory neuron types, like SST NPY or SST HGF, were not
162 distinguished at the subclass level, but were identified at the subtype level. The cellular taxonomy was
163 relatively consistent, and the subtypes were well represented across all three brain sources (**Supplementary**
164 **Figs. 2a,b**). Neuronal cells made up 38.4% (EN 23.0% and IN 15.4%), with oligodendrocytes being the next
165 most abundant, at 36.1%. Major cell types matched well when compared to the previous cellular taxonomy of
166 DLPFC^{1,6}, and subtypes were relatively concordant (**Supplementary Figs. 2f-h**). Neuronal subclasses exhibit

167 distinct functional characteristics from non-neuronal subclasses (**Fig. 2e**). ENs are enriched in pathways
168 associated with synaptic vesicle priming and neurotransmitter secretion, whereas INs are enriched with
169 functions related to receptor signaling and ion transport. Immune cell types show unique enrichments in
170 functions related to cytotoxic immune responses, while mural cells are involved in vessel morphogenesis. It
171 has been shown cell types are differentially implicated in mediating disease risks^{9,10}. Therefore, we further
172 annotated cell types with disease GWASs using the single-cell disease-relevance score (scDRS) and found
173 that neurological diseases largely involve immune and glial cell types, whereas psychiatric diseases are
174 predominantly associated with neuronal cell types (**Fig. 2f, Supplementary Fig. 2i**).
175




177 **Fig. 2. Unified processing of the single-cell transcriptomics atlas and hierarchical cellular taxonomy.**
178 **(a)** Hierarchical structure of transcriptome-based cellular taxonomy. Taxonomic annotation at three levels of
179 granularity; class (n=8), subclass (n=27), and subtype (n=65). **(b)** Spatial distribution of major cell classes. **(c)**
180 Spatial distribution of EN subclasses. **(d)** Markers defining neuronal subclasses. **(e)** Functional enrichment of
181 cellular subclasses using Gene Ontology Biological Process (GO BP). **(f)** Enrichment of heritable traits for
182 cellular subclasses using previous GWAS studies (scDRS). AD¹¹, MS: multiple sclerosis¹², PD¹³, Epilepsy:
183 epilepsy focal¹⁴, Migraines¹⁵, Stroke¹⁶, ALS: amyotrophic lateral sclerosis¹⁷, SCZ¹⁸, BD¹⁹, MDD: major
184 depressive disorder²⁰, ASD: autism spectrum disorder²¹, ADHD: attention deficit hyperactivity disorder²²,
185 Insomnia²³, Education: educational attainment²⁴, IQ: intelligence²⁵, Alcoholism²⁶, OCD: obsessive compulsive
186 disorder²⁷, Tourettes: Tourette Syndrome²⁸, Obesity²⁹, T2D: type 2 diabetes mellitus³⁰, Cholesterol: cholesterol
187 total³¹, RA: rheumatoid arthritis³², IBD: inflammatory bowel disease³³, UC: ulcerative colitis³⁴.

188 **Inter-individual variation of the human cortical transcriptome**

189 Population-level transcriptomic variation is influenced by genetic differences among individuals,
190 phenotypes such as age, sex, and disease status, as well as technical factors such as tissue source,
191 dissection bias, and single-cell library preparation. We first set out to explore the determinants of the overall
192 transcriptome variation in our sample cohort. Population-scale snRNA-seq data allowed partitioning of the
193 gene expression variance by cellular variables (including cell type and fraction of mitochondrial and ribosomal
194 genes), donor-level variables (including subject ID, age, sex, genetic ancestry, and diagnosis), and technical
195 variables (including source of the tissue specimen, post-mortem interval, technical replicates, and sequencing
196 depth) (**Fig. 3a**). Across all genes, a mean of 49.8% of the total expression variance can be attributed to
197 variation across cell type, while inter-individual variation explains 9.8%, and unexplained residual variation
198 accounts for 38.9%. The remaining variables explained less than 1% of the total variance on average. We
199 prioritized several drivers of expression variation (**Fig. 3b**). Several genes with high cell type variation
200 (including ATP8A2, GABRB3, and DOCK3) are dominated by genes differentially expressed between neuronal
201 and non-neuronal cell types (**Fig. 3c**). As expected, genes varying across sexes were located in sex
202 chromosomes (**Supplementary Fig. 3c**). Interestingly, genes with high variation across tissue sources were
203 mostly mitochondrial genes (**Supplementary Fig. 3d**), possibly due to technical differences in physiological
204 and environmental factors from dissection and handling at the respective tissue sources^{35,36}. Top 3 genes with
205 the highest variation across diagnosis (CIRBP, FGF1, and WSB1) were implicated in stress response and
206 hypoxia. CIRBP, which also had a high variation across PMI (ranked 4th), was a gene induced in response to
207 low temperature and hypoxia, and its expression was inversely associated with patient survival in cancer³⁷.
208 FGF1 was another gene linked to temperature stress and hypoxia³⁸, and WSB1 was a neuroprotective protein
209 and regulator of many genes associated with the cellular response to hypoxia³⁹. Top variable gene in PMI,
210 HP1BP3, was chromatin organizing protein induced in hypoxic conditions⁴⁰. This analysis examines expression
211 variation shared across cell types, so the low variance fraction explained by diagnosis indicates the need for
212 cell type specific analysis.

213 We observed that inter-individual differences explained 80.9% of the variation in ARL17B gene expression
214 (**Fig. 3b,d**). Several adjacent genes, such as ARL17A and KANSL1, also have high inter-individual variation
215 and are localized on the disease-associated MAPT locus (17q21.31) (**Fig. 3b**). ARL17B and KANSL1 are often
216 found as a fusion transcript (KANSL1::ARL17B) and frequently undergo polymorphic translocation^{41,42}, and
217 they have been implicated in neurological disorders such as ALS, PD, and MS⁴³⁻⁴⁵. To interrogate possible
218 genetic causes for variation in expression, we examined normalized gene expression at the donor level,
219 stratified by MAPT haplotypes (**Fig. 3e, Methods**). We observed two distinct patterns of ARL17B expression
220 that could be potentially linked to H1 and H2 MAPT haplotypes, with lower expression linked to the H1H1
221 genotype. We observed stratification of haplotypes by genetic ancestry, where the H2H2 genotype was almost


222 exclusively found within EUR ancestry, consistent with previous reports⁴⁶ (**Supplementary Fig. 3f**). We
223 replicated a previous finding that the H1 haplotype is associated with PD susceptibility, and observed that the
224 H1H1 genotype increases PD risk with an odds ratio (OR) of 4.125 (**Supplementary Fig. 3g**; $P \leq 0.0273$),
225 much higher than previously reported (1.42⁴⁷ or 1.46⁴⁸). In addition, we tested the contribution of the H1
226 haplotype to AD among non-ApoE4 carriers⁴⁹ but did not find a significant association ($P \leq 0.302$). The
227 variation in inter-individual expression is inversely correlated with genetic constraints, as measured by the
228 gnomAD Loss-of-function Observed/Expected Upper-bound Fraction (LOEUF) score (**Fig. 3f, Supplementary**
229 **Fig. 3h**). Genes with high inter-individual variability tend to be less constrained and are often associated with
230 the maintenance of basal cellular functions (i.e., housekeeping genes), including translation, RNA processing,
231 metabolism, signal transduction, and structural maintenance, consistent with previous findings^{50,51} (**Fig. 3g**).
232



234 **Fig. 3. Sources of transcriptomic variation.** (a) Variance partition of the transcriptome. (b) Top genes for
 235 each technical and clinical covariate category. (c) ATP8A2 gene expression across cell types. (d) ARL17B
 236 gene expression across donors. (e) Stratification of ARL17B expression by MAPT haplotypes. (f) Genetic
 237 constraints of gene groups measured by average LOEUF score (upper bound of 90% confidence interval for
 238 o/e ratio for high confidence pLoF variants; lower values indicate more constrained). “Low”, indicates the
 239 bottom 2,000 genes with the lowest brain donor variance. “High”, indicates the top 2,000 genes with the
 240 highest brain donor variance. “Random”, indicates 2,000 random genes that are in neither the “Low” nor “High”
 241 category. (g) Functional enrichment for genes with high or low inter-individual variation.

242 Cross-disorder variation of cell type composition across 8 different 243 neurodegenerative and neuropsychiatric diseases

244 Utilizing 318 neurotypical donors as a baseline, we systematically evaluated variation in the cellular
 245 composition of the DLPFC across eight different neurodegenerative (NDDs, including AD, DLBD, Vas, Tau,
 246 PD, and FTD) and neuropsychiatric diseases (NPDs, including SCZ and BD). Using all subclass-level cell
 247 types, we found the overall cell type composition changes were broadly stratified by NDDs and NPDs, and that
 248 they form distinct clusters (**Fig. 4a**). Notably, we observed a higher degree of similarity among AD, DLBD, and
 249 Vas. Focusing solely on neurons, we saw equal or greater correlations among the same class of diseases,
 250 underscoring the critical role of neurons in the etiology of neurological diseases. Additionally, similarities
 251 between FTD-AD (all cells) and FTD-Tau (neurons) were observed. Exploring each subclass further, we
 252 identified a notable overlap in the prevalence of neuronal and glial cell types within the same class of diseases
 253 (**Fig. 4b, Supplementary Table 3**). Specifically, we observed that NDDs were characterized by a higher
 254 abundance of non-neuronal cells, particularly vascular cell types (**Supplementary Fig. 4c**), as well as
 255 elevation of a specific IN, namely IN_LAMP5_RELN, IN_LAMP5_LHX6, and IN_ADARB2 subclasses. In
 256 contrast, NPDs were predominantly associated with an increase in neuronal cells, particularly deep layer ENs
 257 in L5-6. To further identify specific subtypes responsible for driving the compositional changes in vascular cell
 258 types, we used subtype-level annotation to analyze compositional variation in 8 NDDs and NPDs (**Fig. 4c**,
 259 **Supplementary Fig. 4d**). From this, we identified dominant subtypes of each subclass that further
 260 differentiated NDDs and NPDs. For example, vascular leptomenigeal cells (VLMCs) are barrier-forming
 261 fibroblasts of the brain⁵², and they are transcriptionally segregated into three subtypes; two meningeal VLMCs
 262 (VLMC_DCDC2 and VLMC_SLC4A4) and one perivascular VLMC (VLMC_ABCA6). Our subtype-level
 263 analysis indicates a polarized response of meningeal VLMC_DCDC2 where their increased proportions are
 264 specifically associated with most NDDs.
 265




267 **Fig. 4. Cross-disorder variation of cell type composition comparing 8 different NDDs (AD, DLBD, Vas,**
268 **Tau, PD, and FTD) and NPDs (SCZ and BD) against common neurotypical controls. (a)** Correlation of cell
269 type composition using all cell types (bottom-left triangle) or limited to neuronal cell types (upper-right triangle).
270 **(b)** Variation in cell type composition for each subclass in 8 different diseases. NDDs and NPDs indicate meta-
271 analysis using broad disease categories. **(c)** Variation of subtype-level composition in the vascular cell class.
272 Color intensity indicates effect size and dot size reflects the statistical significance of correlations.

273 **Cross-disorder variation of gene expression and genetic concordance**

274 Cross-disorder gene expression analysis has the potential to identify shared biological pathways and
275 mechanisms, improve diagnostic accuracy, and help develop targeted treatments. To assess the extent of
276 sharing between NDDs and NPDs, we performed a comprehensive analysis of differentially expressed genes
277 (DEGs) by decomposing the total disease signatures into shared and distinct components. Using Dreamlet
278 followed by Mashr⁵³, we performed composite tests to evaluate the specificity of disease effect (**Methods**),
279 leading to the identification of shared disease signatures that are invariant across cell subclasses (**Fig. 5a,**
280 **Supplementary Figs. 5a,b**). Genes sharing cross-disorder signatures encompassed crucial transcriptional
281 processes, such as mRNA splicing and processing, and protein localization to mitochondria. The observed
282 cross-disorder signatures, affecting genes, which are critical for the proper functioning of cellular processes,
283 align with the omnigenic model⁵⁴, and further support the pleiotropy of those genes influencing multiple
284 disorders, both genetically and transcriptionally. After discounting the shared cross-disorder signatures from
285 the overall DEG expression profiles, we used the residual effects to quantify the pair-wise transcriptomic
286 similarity between traits (**Fig. 5b, Supplementary Table 4**). Similarities between pairs of NDDs or NPDs were
287 greater compared to the NDD-NPD contrast, with AD, DLBD, Vas, and PD being the most similar. Meta-
288 analysis using disease-specific effects of these four transcriptomically similar traits (AD, DLBD, Vas, and PD)
289 implicated neuronal development and synaptic signaling pathways involving interneurons (IN_LAMP5_RELN,
290 IN_ADARB2, and IN_PVALB) as well as vasculature development from the VLMC subclass (**Fig. 5c,**
291 **Supplementary Fig. 5c**).

292 Comparison of pairwise trait co-heritability against pairwise transcriptome similarity can identify shared
293 genetic influences and underlying biological mechanisms, leading to better insights into disease etiology and
294 potential therapeutic targets. We first used GWAS summary statistics to estimate the shared heritability (r_g)
295 among NDDs and NPDs, revealing disease pairs (i.e., SCZ-BD, DLBD-PD) with a high degree of heritability
296 overlap (**Fig. 5d**). This analysis differentiates between NDDs and NPDs, revealing lower shared heritability
297 between NDDs and NPDs. We then quantified the pairwise transcriptome similarity (ρ_s) across NDDs and
298 NPDs (**Fig. 5e**). Our findings revealed varying degrees of transcriptomic overlap, with some exhibiting high
299 similarity, particularly in disease pairs such as AD and DLBD. We calculated the pair-wise trait heritability-
300 transcriptome concordance ($r_g - \rho_s$) by comparing the shared heritability against the average transcriptome
301 similarity across cell types. We observed a positive correlation between genetic and transcriptomic similarities
302 (Spearman's $\rho = 0.56$), indicating that diseases with higher shared genetic risk also tend to have more similar
303 gene expression profiles (**Fig. 5f**). We extended the $r_g - \rho_s$ comparison by considering the transcriptional
304 concordance for each cell type (**Fig. 5g, Supplementary Fig. 5d**). Among all cell types, the transcriptional
305 concordance of Chandelier cells (IN_PVALB_CHC) had the highest similarity with the pairwise trait heritability.
306 In summary, our approach allowed us to dissect disease signatures into shared and distinct components,
307 revealing significant overlap in gene expression and genetic risk across NDDs and NPDs. These findings
308 bolster our understanding of common and unique disease mechanisms, paving the way for novel therapeutic
309 strategies targeting shared or distinct pathways.

310



311 **Fig. 5. Cross-disorder variation of gene expression.** (a) Pathways implicated by shared gene expression
 312 changes across 8 disorders. Hypergeometric test with FDR ≤ 0.01 shown. (b) Transcriptome similarities
 313 between disease pairs. Correlation is measured using Spearman correlation. Cross-disease shared genes are
 314 discounted from the comparison. (c) Pathways implicated by shared signatures from AD, DLBD, Vas, and PD.
 315 Hypergeometric test with FDR ≤ 0.001 shown. (d) Shared heritability estimates for disease pairs. LD Score
 316 Regression (LDSC). (e) Transcriptome similarity measured by Spearman correlation. (f) Correlation between
 317 shared heritability and median of transcriptome similarity. (g) Correlation between shared heritability and
 318 transcriptome similarity per cell subclass.

320 Transcriptomic variation with AD pathology

321 Next, we focused on characterizing the transcriptomic variation in AD using case-control comparison, and
 322 analysis of different phenotypes that capture disease severity, including plaque density using CERAD scores,
 323 neurofibrillary tangle progression using Braak stage, and level of cognitive impairment. The analysis of
 324 variation in cell type composition reveals distinct patterns associated with AD pathology compared to normal
 325 aging (Fig. 6a, Supplementary Fig. 6a, Supplementary Table 5). Notably, changes unique to AD pathology,
 326 such as the observed increase in Micro and IN_LAMP5_LHX6 with higher CERAD scores, indicate a potential
 327 association between this neuronal subtype and A β pathology. Additionally, the loss of EN_L2_3_IT in AD
 328 (based on case-control and CERAD comparisons), which is not evident in normal aging, suggests a specific
 329 vulnerability for this neuronal subtype to AD. Placing subclasses based on compositional shifts of normal aging


330 and AD (**Fig. 6b**), we identified one of the vascular cell types, SMC, was having the opposite effect, suggesting
331 an AD-specific vulnerability in SMC. Likewise, changes in most ENs were discordant suggesting the
332 mechanisms that lead to neuronal loss are AD-specific. Taken together, our findings highlight the cell type-
333 specificity of vulnerability associated with AD.

334 To better understand transcriptomic variation under AD pathology and to identify subclass most affected,
335 we also analyzed the changes in AD cases due to co-occurring conditions. It is estimated that more than 80%
336 of AD patients will exhibit at least one NPS over the course of their illness that significantly impacts their clinical
337 outcomes^{5,55} which suggests at least some shared molecular mechanisms between serious mental illness and
338 AD. To evaluate cell type associations with the prevalence of NPS, we applied compositional variation analysis
339 to three categories of NPS based on co-occurrence estimates. Notably, using age-matched groups of AD
340 patients with or without NPS (**Supplementary Fig. 6b**), we found AD patients experiencing weight loss and
341 PMA have an increased ratio of EN cell types, especially in deep layer neurons in L6 (**Fig. 6a, Supplementary**
342 **Fig. 6a**). Our results support previous findings⁵⁶ that the deeper PFC layers (L5-6) are involved with certain
343 types of NPS.

344 Upon identification of vulnerable cell subclasses in AD, we questioned their roles in AD pathology whether
345 their changes are damaging, protective, causal, or derived. As demonstrated in previous studies⁵⁷, we
346 employed mediation analysis to decipher the causal relationships between various cascades of events leading
347 to disease onset and progression of AD pathology. We performed the analysis on the base hypothesis that
348 polygenic risk (AD PRS; **Methods**) contributes to plaque accumulation (mean density of neuritic plaques),
349 which in turn affects tau progression (Braak), leading to varying degrees of dementia. We tested 14 subclasses
350 that were significantly altered in any of the contrasts and observed significant average causal mediation effects
351 (ACME, $P < 0.05$) involving Microglia, VLNC, IN_SST, and IN_LAMP5_LHX6 (**Fig. 6c**). Initially, we showed
352 PRS affects both plaque and tau pathology, but tau is also significantly affected by plaque accumulation
353 (ACME = 0.0903, $P < 2e-16$). Then, tau progression results in more VLNC cells mediated by an increase in
354 Microglia (ACME = 0.00477, $P = 0.005$). Conversely, an increase in microglia leads to a decrease
355 IN_LAMP5_LHX6. Such changes in the levels of both VLNC (ACME = 0.00515, $P = 0.0002$) and
356 IN_LAMP5_LHX6 (ACME = -0.00269, $P = 0.031$) appear to exacerbate dementia. Furthermore, plaque
357 accumulation is mitigated by IN_SST cells (ACME = 0.1475, $P < 2e-16$). Increased microglia lowers IN_SST
358 (coef = -0.18, $P = 5.04e-07$), as does increased tau (coef = -0.06, $P = 1.82e-04$), contributing to more plaque
359 accumulation (coef = -2.01, $P = 7.47e-06$).

360 To determine how gene programs change in response to increasing severity of AD pathology, we
361 characterized the DEGs in 27 subclasses (**Fig. 6d, Supplementary Fig. 6d, Supplementary Table 6**). DEGs
362 in general have high concordance across different AD pathology variables, consistent with previous reports¹.
363 Overall, DEGs in AD ($FDR < 0.05$) can be summarized as up-regulation of genes in vascular cell classes
364 (Mural and Endo) while down-regulation of genes in neurons (**Supplementary Fig. 6c**). We discovered genes
365 differentially expressed in microglia were not observed in other subclasses, and these genes generally
366 exhibited higher effect sizes. These include previously characterized up-regulated genes in Microglia, including
367 DPYD, IL15, and PTPRG^{53,58,59}. Further characterizing microglia-associated gene signatures, we found they
368 are specifically enriched with pathways involved in negative regulation of cell motility and migration as well as
369 response to lipoprotein particle (**Fig. 6e, Supplementary Fig. 6e**). Gene expression changes in neurons were
370 largely affecting synaptic functions including synapse assembly, development, signaling, and membrane
371 transport. Lastly, genes affecting VLNCs were implicated in muscle tissue development.

372



374 **Fig. 6. Transcriptome changes across AD neuropathology.** (a) Compositional variation analysis using
375 normal aging, different measures of AD pathology (binary AD diagnosis (dx_AD), CERAD score, Braak
376 staging, and ordinal dementia scale), and 3 categories of NPS within AD. (b) Comparison of compositional
377 changes between aging and AD. Green indicates changes are concordant. Red indicates changes are
378 discordant. Only subclasses with at least one FDR significant contrast shown. (c) Causal mediation analysis
379 using PRS, mean plaque, Braak staging, and dementia scale. CLR-transformed subclass fractions were used
380 for modeling. Statistical significances are shown above the arrow ($P < 0.001$ ***, < 0.01 **, and < 0.05 *), and
381 numbers below indicate coefficients. Mediation effects of SST interneurons on A β plaque accumulation shown
382 separately. (d) DEGs in AD phenotypes. Meta-analysis between brain banks. Top genes with FDR < 0.01 and
383 effect size ≥ 0.35 . (e) Functional enrichment analysis of DEGs by subclass using Gene Ontology Biological
384 Process. Hypergeometric test with FDR ≤ 0.01 shown. GO terms were reduced using rrvgo.

385 **Nonlinear dynamics of the AD pathological trajectory**


386 To understand AD dementia mediated by tau proteinopathy, we modeled the transcriptome using
387 variational autoencoder (VAE)-based latent manifold mapping (**Fig. 7a, Methods**). We inferred two
388 independent cell-type-specific disease trajectories from semi-quantitative measures of AD progression (tau
389 proteinopathy and severity of cognitive decline) and explored the dynamics of two paths leading to the onset
390 and early stage of AD pathogenesis. To decorrelate Braak and dementia model predictions, we equally
391 sampled all combinations of Braak stage and dementia status during model training (**Supplementary Fig. 7**).
392 The accuracy of the Braak and dementia model predictions were significantly above chance for all eight cell
393 classes ($P < 1e-4$, bootstrap) (**Fig. 7b, top**). We built a disease trajectory using the predicted Braak staging as
394 a pseudo-temporal axis (**Supplementary Figs. 8a,b**) and calculated a dementia resilience score that
395 measured how gene expression is correlated with predicted dementia, conditioned on the predicted Braak
396 staging (**Methods**). Specifically, a gene is considered protective (i.e., resilient against dementia), if increased
397 expression is associated with a decrease in predicted dementia, and vice versa (damaging if increased
398 expression is associated with an increase in predicted dementia). Many past studies have suggested that gene
399 expression can evolve nonlinearly with disease progression⁶⁰. Thus, we measured the degree of nonlinearity
400 for each gene trajectory (**Supplementary Fig. 8c**) and revealed that those within the immune and neuronal cell
401 class were the most nonlinear and linear, respectively (both P s $< 1e-4$, bootstrap) (**Fig. 7b, bottom**).

402 To further characterize the nonlinear evolution of gene expression, we defined an "early" and "late" disease
403 stage (**Supplementary Fig. 8c**) and determined the top 32 GO BP pathways that best summarize the
404 biological changes associated with early and late stages of tau proteinopathy and dementia resilience (**Fig. 7c,**
405 **Supplementary Figs. 9-11, Supplementary Table 7**). A semantic clustering of the pathways identified five
406 functional clusters. The first cluster was primarily related to synaptic function, which were characterized by
407 down-regulation in OPCs in the early stages of AD, and then up-regulation in neurons in later stages. For both
408 cell types, increased expression was associated with diminished resilience (i.e., damaging). The late increase
409 of genes implicated in these pathways could be linked to compensatory mechanisms following synaptic loss⁶¹.
410 The second cluster was related to cell metabolism pathways implicated in protein translation^{2,62}, mitochondrial
411 function^{2,63}, and acidification⁶⁴, which showed strong downregulation in neurons with increasing Braak,
412 consistent with past studies⁶⁵. Decreased expression in these metabolic pathways implied damaging
413 association with decreased resilience (increase in metabolism was protective). The third cluster was related to
414 cell stress, including pathways related to chaperone-mediated protein assembly, folding, and tau-kinase
415 activity. In non-neuronal cells, increased cell stress was strongly associated with cognitive decline in both the
416 early and late stages. The fourth cluster was related to immune response and inflammation. In immune cells,
417 early increase in pathways such as microglial activation, phagocytosis, and B cell proliferation was observed,
418 while late increase was involved with pathways implicated in adaptive immune responses such as antigen

419 presentation and T-cell response, all of which were associated with dementia resilience. Lastly, vascular cells
420 were implicated in damaging changes such as reduced lipid transport and vascular permeability, response to
421 interleukin-17 (IL-17), glycolysis, endothelial cell differentiation, and nitric oxide synthesis.

422 As previous studies have highlighted the importance of the immune response in AD^{58,66–72}, we examined
423 this cell class in more detail (**Figs. 7d-g**); We also extended the analysis to EN, IN and OPC cells classes
424 (**Supplementary Figs. 12-15**). To help visualize the non-linear dynamics of the immune response to AD, we
425 categorized gene expression trajectories into four modules based on their response to increasing tau
426 proteinopathy: early increasing, early decreasing, late increasing, and late decreasing (**Fig. 7d**). Gene
427 enrichment of these four trajectory modules showed that pathways involved in macrophage colony stimulation
428 and metal transport were all upregulated in the early stage (**Fig. 7e**), whereas migration, purinergic signaling,
429 and negative regulation of inclusion body assembly were downregulated. In the later stage, lipid-related
430 pathways such as adipose tissue development, and triglyceride metabolism increased, while synapse-related
431 pathways were downregulated. Gene-set enrichment analysis using GWAS summary statistics for the top 250
432 genes in each trajectory module revealed that late increasing genes were the most strongly associated with AD
433 (FDR $\leq 4.1e-6$), although the other three modules were also significantly associated (FDR early increase \leq
434 0.005, early decrease ≤ 0.048 , late decrease ≤ 0.040 (**Fig. 7f**, **Supplementary Table 8**, **Supplementary Fig.**
435 **12b**). Interestingly, the late increasing trajectory module was also significantly correlated with other NDDs,
436 including MS and PD. We further examined the genes associated with trajectory modules (**Fig. 7g**, list of top
437 genes for all cell classes are found in **Supplementary Table 9**). Markers for homeostatic microglia⁷³, such as
438 CX3CR1, NAV2 and P2RY12 were among the top 10 early decreasing genes with increasing proteinopathy
439 (FRMD4A ranked 26th out 17,265 coding genes, **Supplementary Table 9**). Conversely, some of the early
440 increasing genes, such as ACSL1, DPYD, and CD163 were recently implicated in a pathogenic lipid-droplet
441 accumulation phenotype in individuals with AD who carry the APOE4/4 genotype (another implicated gene,
442 NAMPT, ranked 54th. **Supplementary Table 9**)⁷⁰. These genes, along with the later upregulation in lipid-
443 related pathways such as adipose tissue development and triglyceride metabolism, lend support to the
444 hypothesis that microglia develop a lipid-droplet accumulating state that potentially exacerbates disease
445 progression^{70–72}.

446



448 **Fig. 7. Modeling of AD using disease trajectory analysis. (a)** Overview of the trajectory inference model. **(b)**
449 Accuracy of the model (above) and nonlinearity index by class (below). **(c)** Pathway enrichment by early (upper
450 left triangles) and late (lower right triangles) phases of the AD trajectory, as predicted by Braak and dementia
451 resilience. A gene is considered protective if increased expression is associated with a decrease in predicted
452 dementia, and vice versa. Hue indicates the z-score (clipped between -10 and 10), and stars indicate $FDR <$
453 0.05 . **(d)** Four representative disease trajectory modules for immune cell class. The mean normalized
454 expression of the 250 genes with greatest early increasing (blue curve), early decreasing (orange), late
455 increasing (green) and late decreasing (red) slopes based on Braak trajectories. **(e)** Pathway enrichment of
456 disease trajectory modules. Text colored by the four trajectory modules. Hue indicates the number of genes in
457 the pathway. **(f)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color
458 indicates neurological traits (red) and psychiatric traits (blue). Hue indicates $-\log_{10}(FDR)$ (clipped at
459 5), asterisk indicates $FDR < 0.05$. **(g)** Top 12 genes for each trajectory module. Hue indicates the rate of
460 normalized expression change (slope) based on the predicted Braak staging. For visualization, we only show
461 each gene once even if it appears in more than one module.

462 Discussion

463 We report a comprehensive disease atlas of the human DLPFC using 1,494 donors affected with various
464 complex neurological and psychiatric conditions. Our single-nucleus transcriptomic analyses provide novel
465 insights about cellular heterogeneity and variability in the human brain, including the observation that about
466 10% of total transcriptomic variation can be attributed to inter-individual differences. Intriguingly, we find genes
467 with higher inter-individual variability and lower genetic constraints that were implicated in certain
468 housekeeping roles⁵¹. This is in contrast to the idea that, due to their essential nature, housekeeping genes are
469 more likely to be conserved^{74,75}. They are among the most universal genes in the cell, and cells adapt their
470 protein synthesis machinery in response to physiological needs⁷⁶. This flexibility is crucial for processes such
471 as differentiation, proliferation, and response to stress. A higher degree of regulatory flexibility suggests a
472 tolerance for variation within certain constraints.

473 We used the disease atlas to characterize cellular and disease-specific responses to pathologic conditions.
474 Our findings reveal shared and distinct cellular composition profiles among NDDs and NPDs, furthering our
475 understanding of their underlying pathophysiological mechanisms. Disease signatures shared across NDDs
476 and NPDs are enriched with genes critical for the proper functioning of cellular processes, such as RNA
477 splicing. This observation aligns with the omnigenic model⁵⁴, where most heritability in complex traits can be
478 explained by effects on peripheral genes that often play indirect, subtle, and cumulative roles in disease. Thus,
479 discounting cross-disease effects could facilitate identification of core disease-relevant functional genes. Using
480 this approach, we found that disease pairs with higher genetic risk overlap tend to have greater transcriptomic
481 concordance, in a cell-type-dependent manner, suggesting that genetic factors contributing to disease
482 susceptibility can also influence transcriptomic alterations in similar ways³.

483 In addition, we revealed that the brain vascular system is intricately linked to immune dysfunction in NDDs.
484 In general, we saw a relative increase in vascular cell types in most NDDs and demonstrate that, in a
485 seemingly protective role, levels of VLMCs rise in individuals who experience exacerbated cognitive
486 impairment in AD. It has previously been shown that the meningeal lymphatic system plays multiple roles in the
487 brain, including waste removal⁷⁷⁻⁷⁹ and the adaptive immune response^{52,80}. Given the role of VLMCs in these
488 processes⁸¹⁻⁸⁴, they warrant further investigation in the context of NDDs.

489 Our analysis of the pathological trajectory of AD aligns with various proposed hypotheses^{65,85-89},
490 particularly for pathways affected in the earliest stages of the disease. Neuronal, immune, and vascular cells
491 exhibit distinct vulnerabilities, with shared alterations across correlated pathways. In neurons, we observed a
492 decrease in metabolic functions (cyclic nucleotide catabolic process, cytoplasmic translation, and ATP

493 synthesis) that have been closely linked to synaptic dysfunction and cognitive decline⁶⁵. The immune response
494 was generally protective against cognitive decline: an early innate immune activation⁸⁵ followed by an adaptive
495 immune response^{67–69} was associated with dementia resilience. The one exception was the response to IL-17,
496 which was damaging in the early stages of AD for the Immune, Mural, and Endo classes. IL-17 has been
497 associated with cognitive decline^{90,91} and disruption of the blood-brain barrier⁹², with anti-IL-17 treatment
498 restoring cognitive function in mice^{90,91}. In addition, chaperones have been closely associated with a number of
499 disease related processes, including tau misfolding and aggregation, and neurotoxicity^{86–89,93,94}, however, their
500 precise roles in AD pathogenesis remains unclear. Our results suggest that chaperones can play opposing
501 roles; protective for neurons but damaging for glia and immune cells. Lastly, vascular cells are associated with
502 negative regulation of vascular permeability and lipid transport, which are detrimental to the infiltration of
503 perivascular immune cells⁹⁵ and the clearance of protein aggregates. Taken together, these insights deepen
504 our understanding of AD pathogenesis and implicate cellular responses that warrant further investigation.
505 Overall, the PsychAD single-cell disease atlas serves as a unique and foundational resource to further our
506 understanding of population-level disease-associated transcriptomic variation in the human brain.

507 **Methods**

508 **Collection and harmonization of clinical, pathological, and demographic metadata**

509 Brain tissue specimens were sourced from two brain banks: the Mount Sinai NIH Neurobiobank (MSSM;
510 1,042 samples) and the NIMH-IRP Human Brain Collection Core (HBCC; 300 samples). Additionally, samples
511 were obtained from five prospective cohort studies conducted at the Rush Alzheimer's Disease Center (RADDC;
512 152 samples)^{96,97}. As such, the available clinical data varied as a function of source (**Supplementary Fig. 4a**).
513 We used the following scheme to harmonize available clinical, pathological, and demographic metadata: the
514 CERAD scoring scheme for neuritic plaque density⁹⁸ was harmonized for consistency across multiple brain
515 banks, where the scores range from 1 to 4, with increasing CERAD number corresponding to an increase in
516 AD burden; 1=no neuritic plaque (normal brain), 2=sparse (possible AD), 3=moderate (probable AD),
517 4=frequent (definite AD). Samples from RADDC used consensus summary diagnosis of no cognitive impairment
518 (NCI), mild cognitive impairment (MCI), and dementia and its principal cause, Alzheimer's dementia^{99–101}.
519 MSSM samples used clinical dementia rating (CDR), which was based on a scale of 0-5; 0=no dementia,
520 0.5=questionable dementia (very mild), 1=mild dementia, 2=moderate dementia, 3=severe dementia,
521 4=profound dementia, 5=terminal dementia. After consulting with clinicians, we created a harmonized ordinal
522 variable where dementia is categorized into three levels of cognitive decline, independent of AD diagnosis;
523 0=no cognitive impairment, 0.5=MCI (mild cognitive impairment), and 1-5=dementia. In addition to AD
524 phenotype, we collected comprehensive demographic (age, sex, and genetic ancestry) and technical variables
525 (tissue source, technician, sample batch, postmortem interval (PMI; measured in minutes), ApoE genotype) to
526 describe each cohort (**Supplementary Table 1**). We briefly describe the process for assigning genetic
527 ancestry¹⁰². In particular, we leveraged quadratic discriminant analysis (QDA) to infer genetic ancestry by
528 training our model using data from the 1000 Genomes Project. We utilized 10-fold stratified cross validation to
529 optimize the regularization parameter within QDA¹⁰³ as well as forward selection to identify the optimal number
530 of principal components for genetic ancestry assignments. For samples without genotypic data we utilized
531 race/ethnicity as a proxy for inferring genetic ancestry. We emphasize that while genetic ancestry is a distinct
532 concept from the social constructs of race and ethnicity¹⁰⁴, we leveraged the correlated race/ethnicity variables
533 as proxies to retain those samples in the analyses. Values for superpopulations included: EAS, SAS, AFR,
534 AMR, EUR, and EAS_SAS, where the category "EAS_SAS" was assigned for samples with unavailable
535 genotypes with an "Asian" value for race/ethnicity, which can potentially correspond to both EAS and SAS.
536

537 **Clinical diagnosis of AD**

538 For analysis comparing donors with AD cases and neurotypical controls, a binary clinical diagnosis variable
539 for AD, dx_AD, was defined, as follows: Individuals with CERAD 2, 3, or 4, Braak \geq 3, and CDR \geq 1 for MSSM
540 or Alzheimer's dementia for RADC were classified as AD cases. Controls were defined as individuals in
541 *controls_neuropathological_clinical* category where CERAD={1}, Braak={0,1,2,3}, and secondary diagnosis
542 (including dementia) is not allowed except for MCI.

543

544 **Measuring AD neuropathology**

545 For analysis comparing donors with pathologic AD, the following variables were used to measure the
546 severity of AD neuropathology: **CERAD score**⁹⁸. A quantitative measure of A β plaque density where 1 is
547 normal, 2 is possible AD, 3 is probable AD, and 4 is definite AD⁹⁹. **Braak AD-staging score** measuring
548 progression of neurofibrillary tangle neuropathology (Braak & Braak-score, or BBScore). A quantitative
549 measure of the regional patterns of neurofibrillary tangle (NFT) density across the brain, where 0 is normal and
550 asymptomatic, 1-2 indicate initial stages where NFT begins to appear in the locus coeruleus and the
551 transentorhinal region, 3-4 indicate progression to limbic regions, such as the hippocampus and amygdala, and
552 5-6 indicate NFT are widespread, affecting multiple cortical regions¹⁰⁵⁻¹⁰⁷.

553

554 **Measuring cognitive impairment**

555 For analysis comparing donors with AD-related dementia, the following variable was used to measure the
556 severity of cognitive impairment: **Clinical assessment of dementia**. A harmonized variable of cognitive status
557 based on the CDR scale for MSSM or NCI, MCI, and Alzheimer's dementia for RADC. We used the three-level
558 ordinal categories of clinical dementia to measure the severity of dementia, in which 0 indicates no dementia,
559 0.5 indicates minor cognitive impairment, and 1.0 indicates definite clinical dementia.

560

561 **Definition of cross-disorder contrasts**

562 For cross-disorder contrasts, we limited the analysis to any individual with Age \geq 17. Neurotypical controls
563 are defined as any individual CERAD={1}, Braak={0,1,2,3}, and secondary diagnosis is not allowed. AD is any
564 individual with CERAD={2,3,4}, Braak={3,4,5,6}, clinically diagnosed as dementia, and secondary diagnosis
565 not allowed. SCZ is any individual with SCZ diagnosis (*SCZ* | *Schizoaffective_bipolar* |
566 *Schizoaffective_depressive*) and secondary diagnosis not allowed, except for metabolic and eating disorders.
567 DLBD is any individual with DLBD diagnosis (*DLBD*) and secondary diagnosis can be only AD. Vascular is any
568 individual with Vascular diagnosis (*Vascular*) and secondary diagnosis can be only AD. BD is any individual
569 with BD diagnosis (*BD_unspecific* | *BD_I* | *BD_II* | *Schizoaffective_bipolar*) and secondary diagnosis not
570 allowed except for metabolic and eating disorders. Tauopathy is any individual with CERAD={1}, Braak={4,5,6}
571 and secondary diagnosis allowed. PD is any individual with PD diagnosis (*PD* |
572 *PD_uncertain_plus_encephalitic*) and secondary diagnosis can be only AD. FTD is any individual with FTD
573 diagnosis (*FTD*) and secondary diagnosis can be only AD. All disease contrasts used in the study can be
574 found in **Supplementary Table 1**.

575

576 **Isolation and fluorescence-activated nuclear sorting (FANS) of nuclei from frozen brain specimens with hashing**

578 All buffers were supplemented with RNase inhibitors (Takara). 25mg of frozen postmortem human brain
579 tissue was homogenized in cold lysis buffer (0.32M Sucrose, 5 mM CaCl₂, 3 mM Magnesium acetate, 0.1 mM,
580 EDTA, 10 mM Tris-HCl, pH8, 1 mM DTT, 0.1% Triton X-100) and filtered through a 40 μ m cell strainer. The
581 flow-through was underlaid with sucrose solution (1.8 M Sucrose, 3 mM Magnesium acetate, 1 mM DTT, 10
582 mM Tris-HCl, pH8) and centrifuged at 107,000 xg for 1 hour at 4°C. Pellets were resuspended in PBS

583 supplemented with 0.5% bovine serum albumin (BSA). 6 samples were processed in parallel. Up to 2M nuclei
584 from each sample were pelleted at 500 xg for 5 minutes at 4°C. Nuclei were re-suspended in 100 µl staining
585 buffer (2% BSA, 0.02% Tween-20 in PBS) and incubated with 1 µg of a unique TotalSeq-A nuclear hashing
586 antibody (Biolegend) for 30 min at 4°C. Prior to FANS, volumes were brought up to 250 µl with PBS and 7-
587 Aminoactinomycin D (7-AAD) (Invitrogen) added according to the manufacturer's instructions. 7-AAD positive
588 nuclei were sorted into tubes pre-coated with 5% BSA using a FACSAria flow cytometer (BD Biosciences).
589

590 **snRNA-seq and hashing library preparation**

591 Following FANS, nuclei were subjected to 2 washes in 200 µl staining buffer, after which they were re-
592 suspended in 15 µl PBS and quantified (Countess II, Life Technologies). Concentrations were normalized and
593 equal amounts of differentially hash-tagged nuclei were pooled. Using 10x Genomics single cell 3' v3.1
594 reagents (10x Genomics), 60,000 (10,000 per donor) nuclei were run in each of x2 10x Genomics lanes to
595 create a technical replicate. At the cDNA amplification step (step 2.2) during library preparation, 1 µl of 2 µm
596 HTO cDNA PCR "additive" primer was added¹⁰⁸. After cDNA amplification, supernatant from 0.6x SPRI
597 selection was retained for HTO library generation. cDNA libraries were prepared according to the 10x
598 Genomics protocol. HTO libraries were prepared as previously described¹⁰⁸. cDNA and HTO libraries were
599 sequenced at NYGC using the Novaseq platform (Illumina).
600

601 **Processing of snRNA-seq data**

602 **Alignment.** Paired-end snRNA-seq library reads were aligned to the hg38 reference genome using STAR
603 solo^{109,110} and sample pools were demultiplexed using genotype matching via vireoSNP¹¹¹. After per-library
604 count matrices were generated, the downstream processing was performed using Pegasus v1.7.0¹¹² and
605 scanpy v1.9.1¹¹³. **QC.** We applied rigorous three-step QC to remove ambient RNA and retain high quality
606 nuclei for subsequent downstream analysis. First, QC was applied at the cell level. Poor-quality nuclei were
607 detected by thresholding based on UMI counts, gene counts, and mitochondrial content. We also checked for
608 possible contamination from ambient RNA, fraction of reads mapped to non-mRNAs, like rRNA, sRNA, and
609 pseudogenes, as well as known confounding features such as lncRNA MALAT1. Second, QC was applied at
610 the feature level by removing features that were not robustly expressed by at least 0.05% of the nuclei. Lastly,
611 QC was applied at the donor level by removing donors with very low nuclei counts, which can introduce noise
612 to downstream analyses. We also removed donors with low genotype concordance. Further filtering was
613 carried out by removing doublets using the Scrublet method¹¹⁴. **Batch correction.** We assessed the
614 correlation between all pairs of technical variables using Canonical Correlation Analysis and used the Harmony
615 method¹¹⁵ to regress out unwanted variables such as the effect of brain tissue source.
616

617 **Defining cellular taxonomy using iterative clustering**

618 Cellular taxonomy was defined using a divide-and-conquer strategy. From the full dataset containing over 6
619 million nuclei, 8 major cell classes were defined using the following steps. We selected 6,000 highly variable
620 genes (HVGs) from mean and dispersions trends¹¹⁶ using the default parameters (min_mean=0.0125,
621 max_mean=3, min_disp=0.5) and brain sources as batch variable after manually excluding sex and
622 mitochondrial chromosomes and MT. We used the k-nearest-neighbor (kNN) graph calculated on the basis of
623 harmony-corrected PCA embedding space to cluster nuclei of the same cell type using Leiden¹¹⁷ clustering
624 algorithms. We used UMAP¹¹⁸ to visualize the resulting clusters. From the class-level clusters, we subsetted
625 the data by each class. Re-calculating HVGs among cells in the same class allowed us to re-focus on a feature
626 space that is more relevant for the same class of cells. We then calculated kNN graph on the basis of the
627 harmony-corrected PCA of the selected HVGs. Leiden-clustering was used to annotate subclass-level
628 annotations. We iterated to the second level of taxonomy yielding 67 subtypes of human brain cells.
629

630 **Spatial validation of cellular taxonomy**

631 **Xenium *in situ* panel selection and custom panel design.** Xenium Human Brain Gene Expression Panel
632 (1000599, 10x Genomics) and a custom panel of 100 genes (**Supplementary Table 10**) were selected for the
633 Xenium experiment. The 100 gene custom panel consisted mainly of subclass markers selected based on
634 specificity and gene expression level. The custom gene list was sent to 10X genomics and the probe design
635 was performed using their in-house pipeline.

636 **Tissue preparation.** Fresh frozen tissue specimens of DLPFC were dissected into small blocks on ice. Tissue
637 blocks were snap frozen by submerging in an isopentane (320404-1L, Sigma-Aldrich) bath chilled with dry ice
638 and stored in -80 °C. Before cryosectioning, tissue blocks were allowed to equilibrate to the cryostat (HM505,
639 Microm) chamber temperature, and were mounted with OCT (Tissue-Tek® O.C.T. Compound, 4583, Sakura
640 Finetek USA). After trimming, good quality 10 µm sections were flattened on the cryostat stage and placed on
641 pre-equilibrated Xenium slides (Xenium Slides & Sample Prep Reagents, 1000460, 10x Genomics). 2-3
642 sections were placed on each slide. Sections were further adhered by placing a finger on the backside of the
643 slide for a few seconds and were then refrozen in the cryostat chamber. Slides were sealed in 50 ml tubes and
644 stored at -80 °C until Xenium sample preparation.

645 **Sample preparation.** Xenium sample preparation was performed according to the manufacturer's protocol;
646 "*Xenium In Situ for Fresh Frozen Tissues – Fixation & Permeabilization, CG000581, Rev C*" and "*Xenium In*
647 *Situ Gene Expression - Probe Hybridization, Ligation & Amplification, User Guide, CG000582, Rev C*". Briefly,
648 fresh frozen sections mounted on Xenium slides from the previous step were removed from -80 °C storage on
649 dry ice prior to incubation at 37 °C for 1 min. Samples were then fixed in 4% paraformaldehyde (Formaldehyde
650 16% in aqueous solution, 100503-917, VWR) in PBS for 30 min. After rinsing in PBS, the samples were
651 permeabilized in 1% SDS (sodium dodecyl sulfate solution) for 2 min, and then rinsed in PBS before being
652 immersed in the pre-chilled 70% methanol and incubated for 60 min on ice. After rinsing the samples in PBS,
653 the Xenium Cassettes were assembled on the slides. Samples were incubated with a probe hybridization mix
654 containing both the Xenium Human Brain Gene Expression Panel (1000599, 10x Genomics) and a 100 custom
655 gene panel at 50°C overnight to allow the probes to hybridize to targeted mRNAs. After probe hybridization,
656 samples were rinsed with PBST, and incubated with Xenium Post Hybridization Wash Buffer at 37°C for 30
657 min. Samples were then rinsed with PBST and ligation mix was added. Ligation was performed at 37°C for 2
658 hrs to circularize the hybridized probes. After rinsing the samples with PBST, Amplification Master Mix was
659 added to enzymatically amplify the circularized probes at 30 °C for 2 hrs. After washing with TE buffer, auto-
660 fluorescence was quenched according to the manufacturer's protocol and nuclei stained with DAPI prior to
661 Xenium *in situ* analysis.

662 **Data processing.** The prepared samples were loaded into the Xenium analyzer and run according to
663 manufacturer's instructions "*Xenium Analyzer User Guide CG000584 Rev B*". After the Xenium analyzer was
664 initiated, the correct gene panel was chosen, and decoding consumables (Xenium Decoding Consumables,
665 PN-1000487, 10x Genomics) and reagents (Xenium Decoding Reagents, PN-1000461, 10x Genomics) were
666 loaded. The bottom of the slides were carefully cleaned with ethanol prior to loading. Once the samples were
667 loaded and the run was initiated, the instrument scanned the whole sample area of the slides using the DAPI
668 channel, and regions of interest were selected to maximize the capture area. Results were generated by the
669 instrument using default settings. By default, the Xenium analyzer uses 15 µm nuclei expansion distance for
670 segmentation of cells. To test the idea of nuclei only segmentation, we resegment the results with 0 µm nuclei
671 expansion, by using the Xenium ranger and the following scripts:


```
672 xeniumranger resegment --id=demo --xenium-bundle=/path/to/xenium/files --  
673 expansion-distance=0 --resegment-nuclei=True
```

674 **Major cell type identification.** After nuclei were segmented, cell x gene matrices were generated from the
675 overlap of each segmented nuclear boundary with detected transcripts in the Xenium experiment. Nuclei were
676 subsequently filtered by the number of detected transcripts, and only those containing at least 40 nuclear
677 transcripts were retained for downstream analysis. Gene expression data from each sample was then log-
678 normalized and normalized data were used for PCA, kNN graph calculation and Leiden clustering. Clusters
679 were then assigned to one of 8 major cell types based on marker gene expression.

680
681 **Label prediction from snRNA-seq data using scANVI.** As an alternative to marker-based annotation, we
682 used scANVI¹¹⁹ to perform reference-based label transfer from the RADC dataset. Briefly, we followed the
683 following steps. First, snRNA-seq gene expression data was subset to the genes shared with the Xenium gene
684 panel. Next, we used the scvi-tools package^{120,121} to train machine learning models for dimensionality reduction
685 based on the reference dataset and its assigned labels (e.g., class and subclass). Models were run with 5
686 layers and 30 latent variables, and the scANVI model was trained for 20 epochs with a minimal sample of 100
687 cells per cluster per epoch. Lastly, a transfer model was trained for 100 epochs and applied to query data to
688 assign labels based on those the model was trained on from the reference. To assess the performance of each
689 transfer model, we asked the model to predict labels in the reference data (using the subset gene pool) and
690 evaluated the rate of correct prediction and biases in label misassignment for each predicted label.

691
692 **Subclass label transfer for EN (IN) cells.** To assign subclass labels for EN and IN nuclei, nuclei from all
693 samples were filtered to EN (IN) based on two alternative methods for major cell type prediction - that
694 described above, and label transfer using scANVI (with the RADC dataset as a reference). After subsetting to
695 nuclei labeled as EN (IN) by both methods, these were then used as a query for a second scANVI label
696 transfer - this one trained on subclass labels. Accuracy for both major cell type and subclass models assessed
697 by predicted labels in the RADC dataset based only on the Xenium gene panel was estimated at > 98%.

698 699 **Processing of genotypes**

700 DNA extraction and genotyping was performed as described previously¹²². In brief, genomic DNA was
701 extracted from frozen brain tissue using the QIAamp DNA Mini Kit (Qiagen), according to the manufacturer's
702 instructions. Samples were genotyped using the Infinium Psych Chip Array (Illumina) at the Mount Sinai
703 Sequencing Core. Pre-imputation processing consisted of running the quality control script HRC-1000G-check-
704 bim.pl from the McCarthy Lab Group (<https://www.well.ox.ac.uk/~wrayner/tools/>), using the Trans-Omics for
705 Precision Medicine (TOPMed)¹²³. Genotypes were then phased and imputed on the TOPMed Imputation
706 Server (<https://imputation.biodatacatalyst.nih.gov>). Samples with a mismatch between one's self-reported
707 and genetically inferred sex, suspected sex chromosome aneuploidies, high relatedness as defined by the
708 KING kinship coefficient¹²⁴ (KING > 0.177), and outlier heterozygosity (+/- 3SD from mean) were removed.
709 Additionally, samples with a sample-level missingness > 0.05 were removed and calculated within a subset of
710 high-quality variants (variant-level missingness ≤ 0.02).

711 For ancestry assignment, genotypes were first merged with GRCh38 v2a 1000 Genomes Project data
712 (<https://wellcomeopenresearch.org/articles/4-50>)¹²⁵ using BCftools version 1.9¹²⁶. PLINK 2.0¹²⁷ was then used
713 to calculate the merged genotypes' principal components (PCs), following filtering (minor allele frequency
714 (MAF) ≥ 0.01, Hardy-Weinberg equilibrium (HWE) $P \geq 1 \times 10^{-10}$, variant-level missingness ≤ 0.01, regions with
715 high linkage disequilibrium (LD) removed) and LD pruning (window size = 1000 kb, step size = 10, $r^2 = 0.2$)
716 steps. For the samples of EUR ancestry assigned using the QDA method, autosomal bi-allelic variants with an
717 imputation $R^2 > 0.8$, HWE $P \geq 1 \times 10^{-6}$, and variant-level missingness ≤ 0.02 were retained. Genotypes were

718 then annotated with ancestry-specific MAF values from the National Center for Biotechnology Information's
719 Allele Frequency Aggregator (ALFA) (https://ftp.ncbi.nih.gov/snp/population_frequency/latest_release/). Only
720 variants with an ancestry-specific ALFA MAF ≥ 0.01 were retained.

721

722 Polygenic risk score calculation

723 Polygenic risk scores (PRS) were computed for the PsychAD cohort using summary statistics from AD
724 GWAS¹¹. The PRS-CS-auto method¹²⁸ was employed, which incorporates continuous shrinkage priors to
725 adjust the effect sizes from these summary statistics. An LD reference panel from the developers of PRS-CS,
726 based on data from the 1000 Genomes Project¹²⁵, was used (<https://github.com/getian107/PRSs>). The
727 default settings for PRS-CS were applied, including parameters $a = 1$ and $b = 0.5$ for the γ - γ prior, 1000
728 Markov Chain Monte Carlo (MCMC) iterations, 500 burn-in iterations, and a thinning factor of 5. The global
729 shrinkage parameter ϕ was determined using a fully Bayesian method. PLINK 2.0¹²⁷ was utilized to calculate
730 the individual-level PRS.

731

732 Genetic heritability analysis of polygenic risk

733 We established a standardized pipeline for Multi-marker Analysis of GenoMic Annotation (MAGMA)
734 followed by single-cell Disease-Relevance Scoring (scDRS). MAGMA incorporates the association P-values of
735 genetic variants from the latest genome-wide association study (GWAS). We used the following GWAS
736 summary stats in scDRS/MAGMA pipeline: AD¹¹, MS¹², PD¹³, Epilepsy¹⁴, Migraines¹⁵, Stroke¹⁶, ALS¹⁷, SCZ¹⁸,
737 BD¹⁹, MDD²⁰, ASD²¹, ADHD²², Insomnia²³, Education²⁴, IQ²⁵, Alcoholism²⁶, OCD²⁷, Tourettes²⁸, Obesity²⁹,
738 T2D³⁰, Cholesterol³¹, RA³², IBD³³, UC³⁴. We applied MAGMA using a standard window of 35 kbp
739 upstream and 10 kbp downstream around the gene body. We executed scDRS using the top 1000 gene
740 weights, sorted by Z score. The MAGMA and scDRS pipeline was run using the following parameters. MAGMA
741 was run using `-snp-loc g1000_eur.bim` (SNP location file corresponding to the Phase 3 1000 Genome
742 Project) and `--gene-loc NCBI38.gene.loc` (gene location file from NCBI build 38). Both files were
743 obtained from <https://ctg.cncr.nl/software/magma>. For scDRS, default setting was applied.

744

745 Variance partition analysis of gene expression

746 After aggregating pseudobulk by library, assays (cell types) were stacked using the *StackedAssay* function
747 of *Dreamlet*. The resulting pseudobulk allowed us to perform analysis across cell types. Variance partition
748 analysis was performed on the resulting stacked pseudobulk. We used the following regression formula:

749

750
$$\text{Gene expression} \sim (1|\text{stackedAssay}) + (1|\text{Channel}) + (1|\text{SubID}) + (1|\text{Source}) +$$

751
$$(1|\text{Ethnicity}) + dx_bit + \text{scale}(\text{Age}) + \text{Sex} + \text{scale}(\text{PMI}) + \log(n_genes) +$$

752
$$\text{percent_mito} + \text{mito_genes} + \text{ribo_genes} + \text{mito_ribo}$$

753

754 where *dx_bit* indicates binary disease status excluding metabolic and eating disorders. Technical covariates
755 *log(n_genes)*, *percent_mito*, *mito_genes*, *ribo_genes*, and *mito_ribo* were removed from the plotting and
756 subsequent analysis because they explained less than 1e-4 percent of overall gene expression variation.

757

758 MAPT locus haplotyping

759 From our harmonized genotype calls, we selected common variants in 17q21.31 locus (chr17:45307631-
760 46836264), performed PCA analysis of genotypes using 10 PCs, and used K-means clustering with $k=3$ to call
761 three genotype clusters, H1H1, H1H2, and H2H2. We additionally confirmed the H1 haplotype using two
762 published SNPs, rs17763050 and rs8070723, known to associate¹²⁹. Haplotypes were estimated using Beagle
763 v5.4¹³⁰ on the selected genotypes of the 17q21.31 region. The estimation of the initial haplotype frequency

764 model converged after one burn-in iteration, and the estimate of the genotype phase converged after 23
765 phasing iterations. For testing association with PD diagnosis, we used logistic regression with age, sex, 10
766 genotype PCs, and H1H1 status:

767
768 $PD \sim \text{Age} + \text{Sex} + \text{Source} + PC1 + PC2 + PC3 + PC4 + PC5 + PC6 + PC7 + PC8 + PC9 +$
769 $PC10 + H1H1$

770
771 In addition, we tested the contribution of the H1 haplotype to AD among non-ApoE4 carriers⁴⁹ but did not find a
772 significant association ($P \leq 0.302$). For testing association with AD diagnosis, we first subsetted for individuals
773 who are not carriers of the ApoE4 allele and tested for AD association using logistic regression with the
774 formula:

775
776 $AD \sim \text{Age} + \text{Sex} + \text{Source} + PC1 + PC2 + PC3 + PC4 + PC5 + PC6 + PC7 + PC8 + PC9 +$
777 $PC10 + H1H1$

778

779 **Compositional variation analysis using Crumblr**

780 We applied the Crumblr method (<https://diseaseneurogenomics.github.io/crumblr>) for testing the variation
781 of cell type composition¹³¹. In summary, Crumblr scales the cell count ratio (i.e., fractions) data using centered
782 log-ratio (CLR) transformation and applies linear models. Since CLR-transformed data is still highly
783 heteroskedastic, the precision of measurements varies widely. Crumblr uses a fast asymptotic normal
784 approximation of CLR-transformed counts from a Dirichlet-multinomial distribution to model the sampling
785 variance of the transformed counts. Crumblr enables incorporating the sampling variance as precision weights
786 to linear (mixed) models in order to increase power and control the false positive rate. Crumblr also uses a
787 variance stabilizing transform based on the precision weights to improve the performance of PCA and
788 clustering. Hypothesis testing was computed using the following formula:

789
790 $\text{Cell composition} \sim \text{scale}(\text{Age}) + \text{Sex} + (\text{phenotype of interest})$

791

792 By including these variables, we account for potential confounders and improve the accuracy and reliability of
793 our hypothesis testing (**Supplementary Fig. 4b**).

794

795 **Differential gene expression analysis using Dreamlet**

796 Due to the increased variable complexity in a large-scale disease atlas, scaling single-cell based
797 approaches to millions of cells across a wide range of phenotypes presents computational challenges¹³² and
798 can be suboptimal^{133–136}. To account for the scale of these data, complex study designs with repeated
799 measures, and low read count per cell, we applied Dreamlet for differential expression analysis, which applies
800 a pseudobulk approach. Building from the previously developed statistical tool Dream¹³⁷, it applies linear mixed
801 models to the differential expression problem in single-cell omics data. It starts by aggregating cells by the
802 donor using a pseudobulk approach^{133,134} and fits a regression model and cell. For each feature and cell
803 cluster, the following mixed model was applied:

804

805 $\text{Gene expression} \sim \text{scale}(\text{Age}) + \text{Sex} + \text{scale}(\text{PMI}) + \log(\text{n_genes}) + \text{percent_mito} +$
806 $\text{mito_genes} + \text{mito_ribo} + \text{ribo_genes} + (\text{phenotype of interest})$

807

808 where categorical and numerical variables were modeled as random and fixed effects, respectively. If the
809 phenotype of interest was a categorical variable, we set the intercept as 0 and used pre-defined contrasts
810 between two factors. We ran a gene set analysis using the full spectrum of gene-level t-statistics¹³⁸.

811

812 **Meta-Analysis (between brain sources):**

813 We conducted a meta-analysis to integrate results from different brain banks for the same disorder. Data
814 tables from multiple brain banks were combined into a single list for each disorder and annotated with their
815 respective sources. The `meta_analysis` function was used to perform the meta-analysis, which involved
816 combining data tables into a single data frame, grouping the data by assay, and calculating standard errors
817 using the formula `abs(logFC / t)`. The meta-analysis was performed using the `rma` function from the
818 `metafor` package with a fixed effects model. P-values were adjusted using the False Discovery Rate (FDR)
819 method, and the negative log10 of the FDR values were calculated. This method was applied to datasets of
820 AD, DLBD, Vas, PD, Tau, FTD, SCZ, and BD.

821

822 **Meta-Analysis (across the same disease category)**

823 To further synthesize findings across multiple disorders, a `meta-of-meta` analysis was conducted,
824 grouping the disorders into neurodegenerative and neuropsychiatric categories. Results from the initial meta-
825 analyses for each disorder were combined into lists based on their categories. The `meta-of-meta` function
826 was used to perform this higher-level analysis. This function combined the meta-analysis results into a single
827 data frame, grouped the data by assay, and calculated standard errors using the formula `abs(estimate /`
828 `statistic)`. This approach was applied to create `meta-of-meta` analyses for all disorders,
829 neurodegenerative disorders, and neuropsychiatric disorders.

830

831 **Evaluation of shared disease signatures using Mashr**

832 Suppose the total disease signature can be written as the sum of shared and distinct components of DEGs
833 for that disease:

834

$$\Delta\tau_k = \sum_{i \in G_{\text{shared}}} \Delta\tau_{i,k} + \sum_{j \in G_{\text{distinct}}} \Delta\tau_{j,k}$$

835

836 where $\Delta\tau_k$ denotes the total disease signature for a disease k , G_{shared} denotes the set of DEGs that are
837 shared among the diseases, G_{distinct} denotes the set of DEGs that are distinct for diseases. This notation
838 highlights that the total differential gene expression for each disease is composed of contributions from both
839 shared genes (common to all diseases) and distinct genes (specific to each disease). To define shared
840 disease signatures, we performed composite tests on Dreamlet results using Mashr to evaluate the specificity
841 of an effect. We evaluated the posterior probability of a non-zero effect present in all 8 cross-disorder
842 contrasts. We categorized a gene as part of the shared component if it had Mashr posterior probability greater
843 than 0.01.

844

845 **Construction of Correlation Matrix**

846 To calculate the correlation matrix, we used a systematic approach to quantify the relationships between
847 genetic estimates across different neuropsychiatric and neurodegenerative disorders. Spearman correlation
848 coefficients were calculated to assess the strength and direction of association between genetic estimates
849 across different disorders. The calculation was performed for the common to each pair of disorders, grouped
850 by assay, after the exclusion of the shared disease signatures.

851

852 The wide-format correlation matrix was converted to a matrix suitable for heatmap visualization. Missing
values were replaced with zeros. Annotations indicating the number of significant genes were added to the

853 rows and columns using the `rowAnnotation` and `HeatmapAnnotation` functions from the
854 `ComplexHeatmap` package. The heatmap was generated with hierarchical clustering of both rows and
855 columns, and colored based on the Spearman correlation values using a gradient from blue (negative
856 correlation) to red (positive correlation).

857

858 **Co-heritability analysis**

859 We employed cross-trait LD score regression using the LDSC tool¹³⁹ to estimate the genetic correlation
860 between a pair of traits. We used summary stats for the following GWAS traits (AD¹¹, DLBD¹⁴⁰, PD¹³, FTD¹⁴¹,
861 SCZ¹⁸, BD¹⁹) and calculated heritability for each of the traits and the genetic covariance and correlation
862 between each of the pair of traits (in total 15 pairs of traits). The size of the cohort was provided to the function
863 `munge_sumstats.py` for heritability estimates. Precomputed LD scores for 1000 Genomes EUR data were
864 downloaded from https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2. The SNP list for
865 `munge_sumstats.py` was downloaded from
866 https://data.broadinstitute.org/alkesgroup/LDSCORE/w_hm3.snplist.bz2. Standard error was obtained from the
867 LDSC output. Script `munge_sumstats.py` was modified to include the parameter: `--chunksize 5e5`.

868 For each of the 15 possible combinations of traits, we calculated the level of correlation of gene expression
869 using the Spearman rank correlation test. Genes were selected by applying the following criteria: $\log_{2}FC \geq 0.5$,
870 $FDR \geq 0.05$. Co-expression coefficient was calculated for the overall dataset and for each of the cell types.
871 Next, to correlate co-expression and co-heritability, we calculated Spearman rank correlation coefficient
872 between LDSC genetic correlation score and co-expression coefficient using 15 possible combinations of traits
873 as data points for the Spearman rank correlation. Spearman was calculated for the overall dataset providing
874 the genetic estimates of the expression similarities in the PsychAD cohort, and also per cell type to obtain the
875 ranking of the cell types that contribute the most to the genetic to transcriptomic similarity in PsychAD.

876

877 **Mediation analysis**

878 Causal Mediation Analysis was performed using two R packages; `mediation` and `psych`. Results were
879 cross-validated between the two methods (identical within a threshold) to ensure the estimated coefficients,
880 and the mediation effects are statistically robust. From 696 individuals in AD contrast, we subsetted 645
881 individuals with European ancestry who have PRS calculations from the latest AD GWAS¹¹. For each
882 regression, we used the following covariates:

883

884 `Age + Sex + PMI + PC1 + PC2 + PC3 + PC4 + PC5 + PC6 + PC7 + PC8 + PC9 + PC10`

885

886 where PC1-10 indicate genotype PCs. For subclass proportion, we used CLR-transformed cell count fractions
887 from `crumblr` analysis. For bootstrapping, we used 10,000 simulations with 50th percentile of the treatment
888 variable used as the control condition and 90th percentile of the treatment variable used as the treatment
889 condition.

890

891 **Trajectory analysis using VAE model**

892

893 **Rationale.** Traditionally, changes in gene expression as a function of disease state are measured using linear-
894 based models. This approach has proven highly valuable and has enhanced our understanding of the
895 biological mechanisms underlying many diseases. However, it is increasingly recognized that changes in gene
896 expression can be highly nonlinear⁶⁰; the interaction among numerous signaling pathways, many involving
897 multiple feedback loops, can lead to complex dynamics that linear models may fail to capture. One approach to
898 capturing potentially nonlinear changes in gene expression is pseudotime analysis (i.e., trajectory
899 inference)^{142,143}. In this approach, cells are assigned a relative pseudotime based on a metric that measures

900 the distance between gene expression vectors, coupled with specific assumptions about how trajectories can
901 evolve. However, this approach requires prior assumptions that might obscure informative aspects of disease
902 progression. For example, most methods require a dimensionality reduction operation (e.g., PCA or UMAP)
903 before calculating each cell's nearest neighbors. The variance of lowly expressed genes, regardless of their
904 importance to the disease, can be overshadowed by the variance of genes with greater expression but less
905 relevance, or by the variance inherent in a sample from a highly diverse demographic. Furthermore, in the
906 case of AD, it is known that the spread of neurofibrillary tangles and A β plaques is strongly, but not perfectly,
907 correlated with dementia. Of special interest is understanding cases where individuals are resilient to dementia
908 despite a high neurofibrillary tangle or A β plaque burden. Thus, we aimed to disentangle changes in gene
909 expression associated with disease burden from those associated with the onset of dementia. Standard
910 pseudotime analysis does not allow us to separate these two covariates effectively. To capture the potentially
911 nonlinear gene expression dynamics during the course of AD progression and to disentangle the effects of
912 disease burden and dementia, we used an alternative approach. As detailed below, we employed a VAE to
913 predict the Braak stage and dementia status from the raw transcript counts of single cells. The model's
914 predictions of the Braak stage and dementia status were then used as two independent pseudotime axes.
915 Importantly, we trained the model by equally sampling all combinations of Braak stage and dementia status,
916 thereby discouraging the model from learning spurious correlations between the two target variables.

917

918 **Model architecture.** We used a VAE, based on the scVI model¹⁴⁴, to predict the Braak stage and dementia
919 status from single-cell gene counts. Both the gene encoder and decoder contained two 512-dimensional
920 hidden layers. All hidden layers applied the ReLU activation function before a LayerNorm operation. Model
921 predictions for Braak and dementia were generated using linear functions from the 32-dimensional latent layer.

922 **Model training.** Single-cell gene counts were log_{1p} transformed in the input layer, and top 25,000 genes for
923 each cell class, based on the percentage of cells the gene was expressed, were used for training. Genes found
924 in the X or Y chromosomes were excluded to discourage the model from learning sex specific differences. The
925 network was trained to minimize 1) the gene reconstruction loss, 2) the Kullback-Leiber divergence, and 3) the
926 disease target prediction (Braak and dementia) loss:

927
$$\mathcal{L} = \alpha(\mathcal{L}_{gene} + \mathcal{L}_{KL}) + \mathcal{L}_{target},$$

928 The scalar α was calibrated to properly weigh the contribution of the standard VAE loss terms (i.e., the gene
929 reconstructions and KL losses) and the target and covariate prediction loss (see below). The gene
930 reconstruction loss, \mathcal{L}_{gene} , was the zero-inflated negative binomial¹⁴⁴. For the binary target dementia, the
931 softmax function was applied to the output, and the loss was the cross-entropy. For Braak, target values were
932 first normalized to zero mean and unit standard deviation, and the mean-squared error loss was used. All loss
933 terms were trained simultaneously. To prevent the model from overfitting the data, we applied a dropout with
934 0.25 probability in the input layer (after the log_{1p} transform) and with probability of 0.5 to all hidden layers (after
935 the ReLU and LayerNorm operations). For each cell class, we divided the cells into 10 splits. In each split, 90%
936 of the cells were used for training, and the remaining 10% were used for inference. Within each split, cells from
937 a single donor exclusively belonged to either the training set or the inference set, but never both. Thus, model
938 predictions were always based on cross-validated data from different donors. We trained one model for each of
939 the ten splits to generate predictions for all donors for that cell class. Models were trained using all donors from
940 the MSSM and RADC brain sources, and then ran inference on only the 696 donors that focused on the AD
941 phenotype contrast (**Fig. 1d**). There existed different numbers of cells for each cell class, thus the amount of
942 training differed between classes. For neurons, astrocytes, oligodendrocytes and the immune cell class, we
943 trained for 5 epochs, and then calculated the Braak and dementia model predictions by averaging the
944 inference outputs generated from the last two epochs. For mural and endothelial cells, which contained less
945 data, we trained for 15 and 20 epochs, respectively, and calculated the Braak and dementia model predictions
946 by averaging the outputs generated from the last five epochs. Model accuracy for the OPC cell class evolved

947 more slowly over model training; thus, we also trained this cell class for 15 epochs, and calculated the Braak
948 and dementia model predictions by averaging the outputs generated from the last five epochs. We used
949 empirical testing to determine which values of α generated accurate Braak and dementia model predictions.
950 Immune cells typically have reduced mean gene counts compared to the other cell classes, and we found that
951 setting $\alpha = 0.005$. For all other cell classes, in which mean gene counts were on average greater, we set
952 $\alpha = 0.002$. Network parameters were trained using the AdamW optimizer¹⁴⁵ with parameters $\beta_1 = 0.9$,
953 $\beta_2 = 0.998$, $\epsilon = 1e - 7$ and weight decay of 0.05 applied to all layers before the latent layer. We used a
954 batch size of 512, and a learning rate schedule with a warmup and decay period using the formula
955 $lr_{rate} = d^{-0.5} \cdot \min(n^{-0.5}, n \cdot warmup^{-1.5})$, where we set $d = 5e - 4$, $warmup = 2000$, while n is the
956 current training step. Finally, we clipped the gradient norm to 0.25 to stabilize training.

957

958 **Model accuracy.** We averaged the cell-level Braak and dementia model predictions to obtain donor-averaged
959 scores. For dementia, we calculated the balanced classification score by determining the percentage of donors
960 without dementia with a prediction score ≤ 0.5 , the percentage of donors with dementia with a prediction score
961 > 0.5 , and then averaging these two values. For Braak, we calculated the Pearson R value between the actual
962 Braak stage and the Braak predictions. Error bars were generated using a bootstrap procedure, in which we
963 randomly sampled donors (with replacement), calculated the Braak and dementia prediction accuracy, and
964 repeated this process 20,000 times. For each cell class, we included all donors with at least 5 cells.

965

966 **Disentangling Braak and dementia.** Braak stage and dementia status are significantly correlated (Pearson R
967 = 0.582, $P < 1e-60$). This strong correlation between target variables implies that input features (i.e., changes
968 in gene expression) associated with the two target variables are also likely to be correlated, which makes it
969 challenging for the model to learn which input feature is predictive of which target variable. The result is when
970 the model is trained in a standard fashion, the correlation between the Braak and dementia model predictions
971 are close to 1 (**Supplementary Fig. 7a**, Immune class shown), suggesting that the model has learned spurious
972 correlations between the input features and target variables. Fully removing spurious correlation in machine
973 learning models is still an unresolved question. However, balancing the training data, such that each of the 14
974 combinations of Braak and Dementia (7 Braak values X 2 Dementia values) are equally sampled, can
975 effectively reduce spurious correlations learned during training¹⁴⁶. In practice, we equally sampled from 15
976 groups, in which the extra group consisted of donors whose Braak stage or dementia status had not been
977 determined. Training with group balancing reduced the correlation between the predicted Braak and dementia
978 values (**Supplementary Fig. 7b**), did not adversely affect the model accuracy at the donor-level
979 (**Supplementary Fig. 7c**).

980

981 **Calculating gene trajectories.** We wished to measure how gene expression varied as a function of the
982 predicted Braak stage. First, gene counts were normalized so that each cell's total count was 10,000, followed
983 by the log1p transformation. Second, for each cell class and each donor, we calculated the mean predicted
984 Braak stage, and the mean normalized expression for each gene. Averaging within each donor reduced
985 variability and ensured that donors with greater cell counts did not contribute disproportionately in downstream
986 analysis. Third, we smoothed both the predicted donor-averaged Braak scores, and the donor-averaged gene
987 expression with a Gaussian kernel (**Supplementary Fig. 8**). Specifically, for each donor i , we weighted all
988 other donors j as

$$w_{i,j} = Z_i \exp\left(-\frac{(\hat{b}_j - \hat{b}_i)^2}{2\sigma^2}\right)$$

989

990 where \hat{b}_i is the predicted Braak score of donor i , σ^2 was set to half the variance of the predicted Braak
991 distribution, and the normalization term Z_i was set such that $\sum_j w_{i,j} = 1$. This allowed us to calculate
992 smoothed Braak, \tilde{b}_i and gene expression, $\tilde{\mathbf{g}}_i$, values

$$\tilde{b}_i = \sum_j w_{i,j} \hat{b}_j$$
$$\tilde{\mathbf{g}}_i = \sum_j w_{i,j} \mathbf{g}_j$$

994 where \mathbf{g}_i is the gene expression vector of log1p normalized counts for donor i . After ordering the smoothed
995 Braak scores, Braak gene trajectories are now represented as the tuple

$$(\tilde{b}_i, \tilde{\mathbf{g}}_i)$$

997
998 We only included donors with at least 5 cells for the cell class. We also removed the 10 donors with the least
999 and greatest smoothed predicted Braak scores after smoothing to minimize the edge effects from smoothing.

1000

1001 **Resilience against dementia.** Since tau proteinopathy and dementia status are highly correlated, gene
1002 expression as a function of the two variables is also correlated, and thus partially redundant. Therefore, we
1003 aimed to measure how gene expression covaried with predicted dementia given the predicted Braak staging.
1004 To do so, we first calculated the expected predicted dementia and expected gene expression for donors with
1005 similar Braak staging. Specifically, we defined the expected dementia given Braak, d_i^b , and the expected gene
1006 expression given Braak, \mathbf{g}_i^b ,

$$d_i^b = \sum_j w_{i,j} \hat{b}_j$$
$$\mathbf{g}_i^b = \sum_j w_{i,j} \mathbf{g}_j$$

1007
1008
1009 The only modification to the kernel was that we set $w_{i,i} = 0$ so that each donor doesn't contribute to its own
1010 expected value. We then calculated the residuals between the donor's predicted dementia status and gene
1011 expression with its expected values:

$$d_i^R = d_i - d_i^b$$
$$\mathbf{g}_i^R = \mathbf{g}_i - \mathbf{g}_i^b$$

1012
1013
1014 The dementia resilience score for each donor was then the product of these two terms. When calculating early
1015 and late resilience, donors were separated into early and late groups based on their predicted Braak staging
1016 before averaging within each group. Using this metric, we define genes as protective if gene expression
1017 increases as predicted dementia decreases, given the predicted Braak staging (i.e., the product of the terms
1018 defined above is negative). Conversely, we define genes as damaging if gene expression increases as
1019 predicted dementia increases, given the predicted Braak staging.

1020

1021 **Trajectory nonlinearity.** We were interested in measuring how gene expression potentially changes in a
1022 nonlinear manner as a function of Braak or dementia. As an initial step, we first wished to quantify the degree
1023 of nonlinearity in gene trajectories across the different cell classes. As outlined in **Supplementary Fig. 8**, this
1024 calculation was performed across a series of steps. Starting with the gene trajectories for each gene and each
1025 cell class as described above, in which smoothed gene expression varied as a function of predicted Braak, we
1026 fit each one with a linear fit, and then calculated its explained variance. We calculated the mean explained
1027 variance using all genes within each cell class with mean normalized expression above 0.01 and used this
1028 value as a baseline. Next, we fit each trajectory with a piecewise linear fit consisting of two consecutive linear
1029 segments, separated at some predicted Braak score $\tilde{b} = t$. For each cell class, we determined the optimal t
1030 that maximized the explained variance of the piecewise fits for all genes within that cell class. The nonlinearity

1031 index (**Fig. 7b, bottom**) was then defined as the difference in explained variance between the piecewise linear
1032 fit and the linear fit. Error bars were determined by bootstrapping the model fits, in which we randomly sampled
1033 genes from donors (with replacement), calculating the nonlinearity index, and repeating the process 100 times.
1034 Significance between different cell classes was calculated by comparing the 100 x 100 bootstrapped nonlinear
1035 index values. We used the optimal time t was then used to define an "early" and "late" period. For the Immune
1036 cell class, which had the greatest nonlinearity index, the early period was defined as the first 140 donors with
1037 the lowest Braak model predictions (after the first 10 donors were removed to account for edge effects, see
1038 above). For the other cell classes, we adjusted 140 proportionally based on the number of donors for that cell
1039 class and defined this number as N ; the early period for each cell class was then defined as the N donors with
1040 the lowest Braak model predictions. Since the rank ordering of donor-averaged Braak scores varies between
1041 cell classes, donors may be classified as early stage for some cell classes and late stage for others.

1042
1043 **Trajectory gene enrichment.** We wished to determine which genetic pathways were most significantly up or
1044 down-regulated during the progression of AD. To do so, we first extracted the slopes of the "early" and "late"
1045 linear fits for the Braak trajectories, and the mean early and late resilience scores (defined above). We used
1046 these slopes input to Zenith (<https://bioconductor.org/packages/release/bioc/html/zenith.html>) to calculate the
1047 changes across all GO BP pathways across the eight cell classes. For each GO BP pathway, we calculated
1048 the maximum $-\log_{10}(\text{FDR})$ score across the eight cell classes and across early and late Braak and Dementia
1049 stages. The score of each pathway was assigned this maximum value.

1050 To obtain a condensed list of the most significantly genetic pathways, we first selected all pathways with $\text{FDR} \leq$
1051 0.05. Next, since we were only interested in pathways that could be informative of the mechanisms underlying
1052 AD progression, we excluded pathways containing words referring to overly broad behaviors or cognitive
1053 functions ("learning", "memory", "vocalization", "social", "auditory", "startle response", "behavior", "locomotor",
1054 "startle", "prepulse inhibition"), terms referring to anatomical structures other than the cortex ("substantia nigra
1055 development", "cardiac", "coronary", "aortic", "ventricular", "kidney", "metanephric", "retina", "optic", "bone",
1056 "respiratory", "pulmonary", "olfactory", "sperm", "placenta", "egg", "embryonic", "ovulation", "estrous",
1057 "placenta", "sperm", "mammary", "germ layer", "outflow tract septum", "adrenal", "epithelial", "skeletal", "otic",
1058 "head") or overly broad neural terms ("nervous system process", "cerebral cortex", "recognition", "host",
1059 "organ", "developmental growth"). To condense the remaining pathways into a more manageable size, we
1060 used rrvgo (<https://www.bioconductor.org/packages/release/bioc/html/rrvgo.html>). We selected the Wang
1061 semantic similarity metric¹⁴⁷, and set the threshold at 0.9 to obtain 56 GO BP pathways (**Supplementary Fig.**
1062 **9**). For easier visualization, we selected 32 representative pathways from this set for **Fig 7c**. We also
1063 performed similar steps (pathways with minimum $\text{FDR} < 0.05$ included, Wang metric with threshold at 0.9) to
1064 obtain the top GO Molecular Function and Cellular Component (**Supplementary Figs. 10, 11**) pathways. In all
1065 cases, we only included pathways with at least 10 genes to ensure that results were statistically robust, and no
1066 more than 250 genes to ensure that pathways were not overly broad.

1067
1068 **Mean trajectories and MAGMA enrichment.** For both the mean normalized expression (**Fig. 7d**) and Magma
1069 enrichment analysis (**Fig. 7f**), we used the top 250 coding genes based upon the early and late slopes of the
1070 Braak trajectories. Late decreasing genes tend to also appear to contain an early increase (**Fig. 7d**). However,
1071 we cannot say whether this is biologically meaningful or the result of selection bias, as a strong late decrease
1072 must be preceded by a high baseline. For both the mean expression and Magma enrichment calculations,
1073 results were qualitatively similar if we used the top 500 or 1000 genes instead (data not shown).

1074 **Data availability**

1075 All data are available via the AD Knowledge Portal (<https://adknowledgeportal.org>). The AD Knowledge Portal
1076 is a platform for accessing data, analyses, and tools generated by the Accelerating Medicines Partnership
1077 (AMP-AD) Target Discovery Program and other National Institute on Aging (NIA)-supported programs to
1078 enable open-science practices and accelerate translational learning. The data, analyses and tools are shared
1079 early in the research cycle without a publication embargo on secondary use. Data is available for general
1080 research use according to the following requirements for data access and data attribution
1081 (<https://adknowledgeportal.synapse.org/Data%20Access>). The data are available under controlled use
1082 conditions set by human privacy regulations. To access the data, a data use agreement is needed. The
1083 registration is in place solely to ensure the anonymity of the study participants. In addition, we have a data
1084 descriptor manuscript¹⁰² detailing the data processing and data collection.

1085 **Code availability**

1086 All the source codes used in this study are available via GitHub
1087 <https://github.com/DiseaseNeuroGenomics/PsychADxD>.

1088 **Acknowledgments**

1089 We would like to express our deep gratitude to the patients and their families who generously donated the
1090 invaluable biological material essential for the success of this study. We are profoundly indebted to their
1091 participation and commitment to advancing scientific knowledge and improving human health. We
1092 acknowledge the National Institute on Aging for their generous support in funding this research with the
1093 following NIH grants: R01AG067025, R01AG082185, and R01AG065582. Human tissues were obtained from
1094 the NIH NeuroBioBank at the Mount Sinai Brain Bank (MSSM; supported by NIMH-75N95019C00049), the
1095 Rush Alzheimer's Disease Center (RADC; funding: P30AG10161, P30AG72975, R01AG15819, R01AG17917,
1096 R01AG22018, U01AG46152, and U01AG61356), and NIMH-IRP Human Brain Collection Core (HBCC, project
1097 # ZIC MH002903). This work was also supported by the Novo Nordisk Foundation NNF14CC0001 and
1098 NNF20SA0035590. The results published here are in whole or in part based on data obtained from the AD
1099 Knowledge Portal.

1100 **Author contributions**

1101 Conceptualization: PR, VH, JFF, DL
1102 Methodology: PR, JFF, DL, GEH
1103 Software: GEH, DL, NYM
1104 Validation: DL, XW, JMF, JFF, PK
1105 Formal analysis: DL, MK, NYM, GEH, SK, MP, TC, FT
1106 Investigation: JFF, AH, CC, ZS, MA, SA, XW, JMF
1107 Resources: VH, DAB, SM, LLB, PKA
1108 Data Curation: JB, PNM, DM, DB, KT, DL
1109 Writing: DL, PR, JFF, NYM with supports from all co-authors.
1110 Visualization: DL, MK, NYM
1111 Supervision: PR, DL, JFF, JB, VH, GV, KG, LJJ
1112 Project administration: DL, PR
1113 Funding acquisition: PR, VH

1114 All authors read and approved the final draft of the paper.

1115 **Competing interests declaration**

1116 The authors declare no competing interests.

1117 **Materials & Correspondence**

1118 Correspondence to Donghoon Lee or Panos Roussos.

1119 **Supplementary Information**

1120 **PsychAD Consortium Authors**

1121 Aram Hong (1, 4, 6, 7); Athan Z. Li (10, 12); Biao Zeng (1, 4, 6, 7); Chenfeng He (9, 12); Chirag Gupta (9, 12);
1122 Christian Porras (1, 4, 6, 7); Clara Casey (1, 4, 6, 7); Colleen A. McClung (18); Collin Spencer (1, 4, 6, 7);
1123 Daifeng Wang (9, 10, 12); David A. Bennett (19); David Burstein (1, 2, 4, 6, 7, 8); Deepika Mathur (1, 4, 6, 7);
1124 Donghoon Lee (1, 4, 6, 7); Fotios Tsetsos (1, 2, 4, 6, 7); Gabriel E. Hoffman (1, 2, 4, 6, 7, 8); Genadi Ryan (13,
1125 17); Georgios Voloudakis (1, 2, 3, 4, 6, 7, 8); Hui Yang (1, 4, 6, 7); Jaroslav Bendl (1, 4, 6, 7); Jerome J. Choi
1126 (11, 12); John F. Fullard (1, 4, 6, 7); Kalpana H. Arachchilage (9, 12); Karen Therrien (1, 4, 6, 7); Kiran Girdhar
1127 (1, 4, 6, 7); Lars J. Jensen (21); Lisa L. Barnes (19); Logan C. Dumitrescu (22, 23); Lyra Sheu (1, 4, 6, 7);
1128 Madeline R. Scott (18); Marcela Alvia (1, 4, 6, 7); Marios Anyfantakis (1, 4, 6, 7); Maxim Signaevsky (6, 7);
1129 Mikaela Koutrouli (1, 4, 6, 7, 21); Milos Pjanic (1, 4, 6, 7); Monika Ahirwar (13, 17); Nicolas Y. Masse (1, 4, 6,
1130 7); Noah Cohen Kalafut (10, 12); Panos Roussos (1, 2, 4, 6, 7, 8); Pavan K. Auluck (20); Pavel Katsel (6);
1131 Pengfei Dong (1, 4, 6, 7); Pramod B. Chandrashekar (9, 12); Prashant N.M. (1, 4, 6, 7); Rachel Bercovitch (1,
1132 4, 6, 7); Roman Kosoy (1, 4, 6, 7); Sanan Venkatesh (1, 2, 4, 6, 7); Saniya Khullar (9, 12); Sayali A. Alatar
1133 (10, 12); Seon Kinrot (1, 4, 6, 7); Stathis Argyriou (1, 4, 6, 7); Stefano Marenco (20); Steven Finkbeiner (13, 14,
1134 15, 16, 17); Steven P. Kleopoulos (1, 4, 6, 7); Tereza Clarence (1, 4, 6, 7); Timothy J. Hohman (22, 23); Ting
1135 Jin (9, 12); Vahram Haroutunian (5, 6, 7, 8); Vivek G. Ramaswamy (13, 17); Xiang Huang (12); Xinyi Wang (1,
1136 4, 6, 7); Zhenyi Wu (1, 4, 6, 7); Zhiping Shao (1, 4, 6, 7)


1137

1138 **PsychAD Consortium Affiliations**


1139 1: Center for Disease Neurogenomics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1140 2: Center for Precision Medicine and Translational Therapeutics, James J. Peters VA Medical Center, Bronx,
1141 NY, USA
1142 3: Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, New York,
1143 NY, USA
1144 4: Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY,
1145 USA
1146 5: Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1147 6: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1148 7: Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1149 8: Mental Illness Research, Education and Clinical Center VISN2, James J. Peters VA Medical Center, Bronx,
1150 NY, USA
1151 9: Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, WI, USA
1152 10: Department of Computer Sciences, University of Wisconsin-Madison, Madison, WI, USA
1153 11: Department of Population Health Sciences, University of Wisconsin-Madison, Madison, WI, USA
1154 12: Waisman Center, University of Wisconsin-Madison, Madison, WI, USA
1155 13: Center for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA, USA
1156 14: Department of Neurology, University of California San Francisco, San Francisco, CA, USA
1157 15: Department of Physiology, University of California San Francisco, San Francisco, CA, USA
1158 16: Neuroscience and Biomedical Sciences Graduate Programs, University of California San Francisco, San
1159 Francisco, CA, USA
1160 17: Taube/Koret Center for Neurodegenerative Disease Research, Gladstone Institutes, San Francisco, CA,
1161 USA
1162 18: Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
1163 19: Rush Alzheimer's Disease Center and Department of Neurological Sciences, Rush University Medical
1164 Center, Chicago, IL, USA

- 1165 20: Human Brain Collection Core, National Institute of Mental Health-Intramural Research Program, Bethesda,
1166 MD, USA
- 1167 21: Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University
1168 of Copenhagen, Copenhagen, Denmark
- 1169 22: Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA
- 1170 23: Vanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA

1171 **Supplementary Figures**



1172 **Supplementary Fig. 1.** (a) Extended schematic overview of snRNA-seq experiments leading to unified
 1173 taxonomy. (b) Donor breakdown by NPS categories and sex. (c) Distribution of gene counts by UMI counts
 1174 after QC of 6M nuclei. (d) Cumulative nuclei count by percent mitochondrial genes. (e) Histogram of nuclei
 1175 counts per sample. (f) Distribution of UMI counts per sample. (g) Distribution of gene counts per sample. (h)
 1176 Distribution of nuclei count per sample. (i) Distribution of nuclei count per donor. (j) Treemap showing the color
 1177 scheme of the unified taxonomy.
 1178
 1179



1180

1181

1182

1183


1184

1185

1186


Supplementary Fig. 2. (a) Composition of cell types in each brain bank using class and subclass-level cellular taxonomy. (b) Composition of subtype in each brain bank. (c) Clustering of EN lineage. A UMAP focusing on the diversity of 10 subtypes of excitatory neurons. (d) Clustering of IN lineage. A UMAP focusing on the diversity of 7 subclasses of inhibitory neurons (IN). (e) Spatial distribution of IN subclass. (f) Expression and fraction of marker gene expression in 27 subclasses. Expression z-scaled and averaged across nuclei. (g) Comparison of subclass-level cellular taxonomy with Ma et al 2022. (h) Comparison of subtype-level cellular

1187 taxonomy with Mathys et al 2023. **(i)** Disease enrichment scores based on GWAS (scDRS) for AD, PD, SCZ,
 1188 and BD.
 1189




1190
 1191 **Supplementary Fig. 3.** **(a)** Example of a gene with the highest variation across age. **(b)** Example of a gene
 1192 with the highest variation across genetic ancestry. **(c)** Example of a gene with the highest variation across sex.
 1193 **(d)** Example of a gene with the highest variation across brain banks. **(e)** Example of a gene with the highest
 1194 variation across diagnosis. **(f)** Normalized expression of ARL17B gene within EN_L2_3_IT subclass stratified
 1195 by genetic ancestry. **(g)** The logistic regression coefficient for PD risk using the haplotype of MAPT locus. **(h)**

1196 Spearman correlation test between variance explained by inter-individual variation and average LOEUF
 1197 conservation score.
 1198




1199
 1200 **Supplementary Fig. 4.** Cross-disorder variation of cell type composition comparing 8 different NDDs and
 1201 NPDs against common neurotypical controls. **(a)** Correlation matrix showing the relationships between various

1202 clinical and demographic variables for the selection of the covariates. The color intensity indicates the strength
 1203 of the correlation, with red representing positive correlations and blue negative correlations. **(b)** Variance
 1204 partition of cell type composition, displaying the variance captured by different covariates in the formula. **(c)**
 1205 Bar plot depicting the absolute logFC values of the 8 different NDDs and NPDs across the cell types. **(d)**
 1206 Variation in cell type composition for each subtype in 8 different diseases. NDDs and NPDs indicate meta-
 1207 analysis using broad disease categories. Color intensity indicates effect size and dot size reflects the statistical
 1208 significance of correlations.
 1209




1210
 1211 **Supplementary Fig. 5. Cross-disorder gene expression signature. (a)** GO BP pathways implicated by shared
 1212 gene expression changes across 8 disorders using Zenith. T-statistic values indicate the direction and


1213 magnitude of the gene set enrichment. **(b)** Extended data for **Fig. 5a** with all 27 subclasses and without
1214 reduction in similar GO terms. **(c)** Pathways implicated by shared signatures from AD, DLBD, Vas, and PD. **(d)**
1215 Correlation between shared heritability and transcriptome similarity per cell subclass.
1216



1218 **Supplementary Fig. 6.** Transcriptomic changes across AD neuropathology. **(a)** Extended data for **Fig. 6a.**
 1219 Compositional variation analysis using normal aging, different measures of AD pathology (binary AD diagnosis
 1220 (dx_AD), CERAD score, Braak staging, and ordinal dementia scale), and 3 categories of NPS within AD. **(b)**
 1221 Age distribution of AD cases with or without three NPS categories. **(c)** Mean effect sizes aggregated by
 1222 direction of effect per cell class. **(d)** Extended data for **Fig. 6d.** DEGs in AD phenotypes. Meta-analysis
 1223 between brain banks. Top genes with FDR < 0.01 and effect size ≥ 0.35 . **(e)** Functional enrichment analysis of
 1224 DEGs by subclass using Gene Ontology Biological Process. Hypergeometric test with FDR ≤ 0.01 shown.
 1225



1226 **Supplementary Fig. 7.** The effect of different training methods on model prediction correlations and accuracy
 1227 for the Immune cell class. **(a)** Correlation between Braak (x-axis) and dementia (y-axis) model predictions at
 1228 the cell-level (left panel) and donor-averaged level (right panel) when all cells are equally sampled. To reduce
 1229 the figure size, only 1 out of 20 cells shown in the left panel. **(b)** Same as (a), except that all combinations of
 1230 Braak stage and dementia status are equally sampled during training. This has the effect of reducing the
 1231 correlation between the predicted Braak and dementia values. **(c)** The correlation between the actual and
 1232 predicted Braak values (left panel) and dementia classification accuracy (right panel), both measured at the
 1233 donor-averaged level, are shown for the two training methods.
 1234
 1235




1236 **Supplementary Fig. 8.** The steps involved in calculating the Braak trajectory for an example gene - NAV2
 1237 from the Immune cell class. **(a)** Given cell-based model predictions along with normalized gene counts, we can
 1238 calculate the donor-averaged predicted Braak (x-axis), predicted dementia (y-axis), and normalized gene
 1239 counts (hue). Predicted Braak and dementia values are normalized between 0 and 1. We then smooth the
 1240 predicted Braak scores along with the gene counts with a Gaussian kernel (black curve, width is shown at
 1241 scale). **(b)** After smoothing, we obtain the Braak trajectory for this gene, relating gene expression to the
 1242


1243 predicted Braak value. **(c)** We then compare how well we can fit this trajectory with a single linear model (blue
1244 dashed line) and a piecewise linear model (green dashed line). The piecewise linear model consists of two
1245 consecutive linear fits, in which the transition point has been optimized to maximize the explained variance.
1246 This transition point is then used to define an "early" and "late" disease stages (**Methods**).
1247



1249 **Supplementary Fig. 9.** Extended data for **Fig. 7c.** Expanded list of all 56 GO BP pathways. Upper left
 1250 triangles indicate the early phases, and lower right triangles indicate the late phases of the AD trajectory
 1251 predicted by Braak and dementia resilience. Hue indicates the z-score, and stars indicate FDR < 0.05.
 1252



1253 **Supplementary Fig. 10.** Pathway enrichment using the top GO Cellular Components pathways. Upper left
 1254 triangles indicate the early phases, and lower right triangles indicate the late phases of the AD trajectory
 1255 predicted by Braak and dementia resilience. Hue indicates the z-score, and stars indicate FDR < 0.05.
 1256
 1257




1258

1259 **Supplementary Fig. 11.** Pathway enrichment using the top GO Molecular Function pathways. Upper left

1260 triangles indicate the early phases, and lower right triangles indicate the late phases of the AD trajectory


1261 predicted by Braak and dementia resilience. Hue indicates the z-score, and stars indicate FDR < 0.05.

1262




1263
 1264
 1265
 1266
 1267
 1268
 1269
 1270

Supplementary Fig. 12. GO BP pathways and GWAS enrichment results for dementia resilience. **(a)** Top early protective pathways (i.e. resilience against dementia, blue), early damaging (i.e. associated with dementia, orange), late protective (green) and late damaging (red). Hue indicates the number of genes in the pathway. Negative log FDR clipped at 10. **(b)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color indicates neurological traits (light red) and psychiatric traits (cyan). Hue indicates negative log₁₀(FDR), asterisk indicates FDR < 0.05. Negative log FDR clipped at 5.



1271
 1272 **Supplementary Fig. 13.** GO BP pathways and GWAS enrichment results for the EN cell class based on their
 1273 response to Braak (a,b) and dementia resilience (c,d). **(a)** Pathway enrichment of genes with early increasing
 1274 response to increasing tau proteinopathy (blue), early decreasing (orange), late increasing (green) and late
 1275 decreasing (red). Hue indicates the number of genes in the pathway. Negative log FDR clipped at 10. **(b)**
 1276 Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color indicates
 1277 neurological traits (light red) and psychiatric traits (cyan). Hue indicates negative log₁₀(FDR), asterisk
 1278 indicates FDR < 0.05. Negative log FDR clipped at 5. **(c)** Pathway enrichment of genes with early protective
 1279 resilience against dementia (blue), early damaging associated with dementia (orange), late protective (green),
 1280 and late damaging (red). **(d)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module.
 1281



1282

1283

Supplementary Fig. 14. GO BP pathways and GWAS enrichment results for the IN cell class based on their response to Braak (a,b) and dementia resilience (c,d). **(a)** Pathway enrichment of genes with early increasing

1284

response to increasing tau proteinopathy (blue), early decreasing (orange), late increasing (green) and late

1285

decreasing (red). Hue indicates the number of genes in the pathway. Negative log FDR clipped at 10. **(b)**

1286

Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color indicates

1287

neurological traits (light red) and psychiatric traits (cyan). Hue indicates negative log₁₀(FDR), asterisk

1288

indicates FDR < 0.05. Negative log FDR clipped at 5. **(c)** Pathway enrichment of genes with early protective

1289


resilience against dementia (blue), early damaging associated with dementia (orange), late protective (green),

1290

and late damaging (red). **(d)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module.

1291

1292



1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

Supplementary Fig. 15. GO BP pathways and GWAS enrichment results for the OPC cell class based on their response to Braak (a,b) and dementia resilience (c,d). **(a)** Pathway enrichment of genes with early increasing response to increasing tau proteinopathy (blue), early decreasing (orange), late increasing (green) and late decreasing (red). Hue indicates the number of genes in the pathway. Negative log FDR clipped at 10. **(b)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module. Text color indicates neurological traits (light red) and psychiatric traits (cyan). Hue indicates negative log₁₀(FDR), asterisk indicates FDR < 0.05. Negative log FDR clipped at 5. **(c)** Pathway enrichment of genes with early protective resilience against dementia (blue), early damaging associated with dementia (orange), late protective (green), and late damaging (red). **(d)** Enrichment of heritability estimates (MAGMA) for each disease trajectory module.

1303 **Supplementary Tables**

1304 **Supplementary Table 1.** Clinical and technical metadata of 1,494 donors in the PsychAD cohort. Metadata
1305 includes binary contrasts and continuous variables used in the study.

1306
1307 **Supplementary Table 2.** Hierarchical cellular taxonomy of the PsychAD snRNA-seq data. Metadata including
1308 parent-child relationships, color hex codes, and number of nuclei per subtype.

1309
1310 **Supplementary Table 3.** Compositional variation analysis across 8 cross-disorder traits.

1311
1312 **Supplementary Table 4.** Differentially expressed genes across 8 cross-disorder traits.

1313
1314 **Supplementary Table 5.** Compositional variation analysis across AD phenotypes.

1315
1316 **Supplementary Table 6.** Differentially expressed genes across AD phenotypes.

1317
1318 **Supplementary Table 7.** The top 50 GO BP pathways for each cell class relative to early/late
1319 increases/decreases in predicted Braak staging, and relative to early/late dementia resilience

1320
1321 **Supplementary Table 8.** Gene-set enrichment analysis using GWAS summary data for each cell class.
1322 GWAS scores are calculated using the top 250 coding genes with the greatest slopes measured relative to
1323 early/late increases/decreases in predicted Braak staging, and the top 250 early/late protective/damaging
1324 coding genes.

1325
1326 **Supplementary Table 9.** The top 250 coding genes with the greatest slopes measured relative to early/late
1327 increases/decreases in predicted Braak staging, and the top 250 early/late protective/damaging coding genes.

1328
1329 **Supplementary Table 10.** List of gene markers used from Xenium human brain custom panel.

1330 **Supplementary Data**

1331 **Supplementary Data 1.** Metadata and model predictions for each cell. Each cell class contains a table that
1332 includes the cell barcode, donor information, the cell subclass, and both the actual Braak and dementia status
1333 along with the model predictions.

1334 Reference

- 1335 1. Mathys, H. *et al.* Single-cell atlas reveals correlates of high cognitive function, dementia, and resilience to
1336 Alzheimer's disease pathology. *Cell* **186**, 4365–4385.e27 (2023).
- 1337 2. Gabitto, M. I. *et al.* Integrated multimodal cell atlas of Alzheimer's disease. *bioRxiv* 2023.05.08.539485
1338 (2024) doi:10.1101/2023.05.08.539485.
- 1339 3. Gandal, M. J. *et al.* Shared molecular neuropathology across major psychiatric disorders parallels
1340 polygenic overlap. *Science* **359**, 693–697 (2018).
- 1341 4. Wingo, T. S. *et al.* Shared mechanisms across the major psychiatric and neurodegenerative diseases.
1342 *Nat. Commun.* **13**, 4314 (2022).
- 1343 5. Argyriou, S. *et al.* Beyond memory impairment: the complex phenotypic landscape of Alzheimer's disease.
1344 *Trends Mol. Med.* (2024) doi:10.1016/j.molmed.2024.04.016.
- 1345 6. Ma, S. *et al.* Molecular and cellular evolution of the primate dorsolateral prefrontal cortex. *Science* **377**,
1346 eabo7257 (2022).
- 1347 7. BRAIN Initiative Cell Census Network (BICCN). A multimodal cell census and atlas of the mammalian
1348 primary motor cortex. *Nature* **598**, 86–102 (2021).
- 1349 8. Kwan, K. Y., Sestan, N. & Anton, E. S. Transcriptional co-regulation of neuronal migration and laminar
1350 identity in the neocortex. *Development* **139**, 1535–1546 (2012).
- 1351 9. Jagadeesh, K. A. *et al.* Identifying disease-critical cell types and cellular processes by integrating single-
1352 cell RNA-sequencing and human genetics. *Nat. Genet.* **54**, 1479–1492 (2022).
- 1353 10. Zhang, M. J. *et al.* Polygenic enrichment distinguishes disease associations of individual cells in single-cell
1354 RNA-seq data. *Nat. Genet.* **54**, 1572–1580 (2022).
- 1355 11. Bellenguez, C. *et al.* New insights into the genetic etiology of Alzheimer's disease and related dementias.
1356 *Nat. Genet.* **54**, 412–436 (2022).
- 1357 12. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral
1358 immune cells and microglia in susceptibility. *Science* **365**, (2019).
- 1359 13. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease:
1360 a meta-analysis of genome-wide association studies. *Lancet Neurol.* **18**, 1091–1102 (2019).

- 1361 14. International League Against Epilepsy Consortium on Complex Epilepsies. Electronic address: epilepsy-
1362 austin@unimelb.edu.au. Genetic determinants of common epilepsies: a meta-analysis of genome-wide
1363 association studies. *Lancet Neurol.* **13**, 893–903 (2014).
- 1364 15. Dönertaş, H. M., Fabian, D. K., Valenzuela, M. F., Partridge, L. & Thornton, J. M. Common genetic
1365 associations between age-related diseases. *Nat Aging* **1**, 400–412 (2021).
- 1366 16. Malik, R. *et al.* Genome-wide meta-analysis identifies 3 novel loci associated with stroke. *Ann. Neurol.* **84**,
1367 934–939 (2018).
- 1368 17. van Rheenen, W. *et al.* Common and rare variant association analyses in amyotrophic lateral sclerosis
1369 identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nat. Genet.* **53**, 1636–
1370 1648 (2021).
- 1371 18. Trubetsky, V. *et al.* Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*
1372 **604**, 502–508 (2022).
- 1373 19. Mullins, N. *et al.* Genome-wide association study of more than 40,000 bipolar disorder cases provides new
1374 insights into the underlying biology. *Nat. Genet.* **53**, 817–829 (2021).
- 1375 20. Als, T. D. *et al.* Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric
1376 disorders using genome-wide analyses. *Nat. Med.* **29**, 1832–1844 (2023).
- 1377 21. Grove, J. *et al.* Identification of common genetic risk variants for autism spectrum disorder. *Nat. Genet.* **51**,
1378 431–444 (2019).
- 1379 22. Demontis, D. *et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture
1380 and implicate several cognitive domains. *Nat. Genet.* **55**, 198–208 (2023).
- 1381 23. Jansen, P. R. *et al.* Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and
1382 functional pathways. *Nat. Genet.* **51**, 394–403 (2019).
- 1383 24. Lee, J. J. *et al.* Gene discovery and polygenic prediction from a genome-wide association study of
1384 educational attainment in 1.1 million individuals. *Nat. Genet.* **50**, 1112–1121 (2018).
- 1385 25. Sniekers, S. *et al.* Genome-wide association meta-analysis of 78,308 individuals identifies new loci and
1386 genes influencing human intelligence. *Nat. Genet.* **49**, 1107–1112 (2017).
- 1387 26. Sanchez-Roige, S. *et al.* Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders

- 1388 Identification Test (AUDIT) in Two Population-Based Cohorts. *Am. J. Psychiatry* **176**, 107–118 (2019).
- 1389 27. International Obsessive Compulsive Disorder Foundation Genetics Collaborative (IOCDF-GC) and OCD
1390 Collaborative Genetics Association Studies (OC GAS). Revealing the complex genetic architecture of
1391 obsessive-compulsive disorder using meta-analysis. *Mol. Psychiatry* **23**, 1181–1188 (2018).
- 1392 28. Yu, D. *et al.* Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders
1393 Through Genome-Wide Association Studies. *Am. J. Psychiatry* **176**, 217–227 (2019).
- 1394 29. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex traits. *Nat. Genet.*
1395 **51**, 1339–1348 (2019).
- 1396 30. Morris, A. P. *et al.* Large-scale association analysis provides insights into the genetic architecture and
1397 pathophysiology of type 2 diabetes. *Nat. Genet.* **44**, 981–990 (2012).
- 1398 31. Willer, C. J. *et al.* Discovery and refinement of loci associated with lipid levels. *Nat. Genet.* **45**, 1274–1283
1399 (2013).
- 1400 32. Okada, Y. *et al.* Genetics of rheumatoid arthritis contributes to biology and drug discovery. *Nature* **506**,
1401 376–381 (2014).
- 1402 33. Liu, J. Z. *et al.* Association analyses identify 38 susceptibility loci for inflammatory bowel disease and
1403 highlight shared genetic risk across populations. *Nat. Genet.* **47**, 979–986 (2015).
- 1404 34. Anderson, C. A. *et al.* Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the
1405 number of confirmed associations to 47. *Nat. Genet.* **43**, 246–252 (2011).
- 1406 35. das Neves, R. P. *et al.* Connecting variability in global transcription rate to mitochondrial variability. *PLoS*
1407 *Biol.* **8**, e1000560 (2010).
- 1408 36. Johnston, I. G. *et al.* Mitochondrial variability as a source of extrinsic cellular noise. *PLoS Comput. Biol.* **8**,
1409 e1002416 (2012).
- 1410 37. Zhu, X., Bühner, C. & Wellmann, S. Cold-inducible proteins CIRP and RBM3, a unique couple with
1411 activities far beyond the cold. *Cell. Mol. Life Sci.* **73**, 3839–3859 (2016).
- 1412 38. Mouta Carreira, C., Landriscina, M., Bellum, S., Prudovsky, I. & Maciag, T. The comparative release of
1413 FGF1 by hypoxia and temperature stress. *Growth Factors* **18**, 277–285 (2001).
- 1414 39. Haque, M., Kendal, J. K., Maclsaac, R. M. & Demetrick, D. J. WSB1: from homeostasis to hypoxia. *J.*

- 1415 *Biomed. Sci.* **23**, 61 (2016).
- 1416 40. Dutta, B., Yan, R., Lim, S. K., Tam, J. P. & Sze, S. K. Quantitative profiling of chromatin dynamics
1417 reveals a novel role for HP1BP3 in hypoxia-induced oncogenesis. *Mol. Cell. Proteomics* **13**, 3236–3249
1418 (2014).
- 1419 41. Boettger, L. M., Handsaker, R. E., Zody, M. C. & McCarroll, S. A. Structural haplotypes and recent
1420 evolution of the human 17q21.31 region. *Nat. Genet.* **44**, 881–885 (2012).
- 1421 42. Wade-Martins, R. Genetics: The MAPT locus—a genetic paradigm in disease susceptibility. *Nat. Rev.*
1422 *Neurol.* **8**, 477–478 (2012).
- 1423 43. Tian, Y. *et al.* Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson’s
1424 Disease. *Mov. Disord.* **38**, 1813–1821 (2023).
- 1425 44. Català-Senent, J. F. *et al.* A deep transcriptome meta-analysis reveals sex differences in multiple
1426 sclerosis. *Neurobiol. Dis.* **181**, 106113 (2023).
- 1427 45. Cooper, Y. A. *et al.* Functional regulatory variants implicate distinct transcriptional networks in dementia.
1428 *Science* **377**, eabi8654 (2022).
- 1429 46. Steinberg, K. M. *et al.* Structural diversity and African origin of the 17q21.31 inversion polymorphism. *Nat.*
1430 *Genet.* **44**, 872–880 (2012).
- 1431 47. Healy, D. G. *et al.* Tau gene and Parkinson’s disease: a case-control study and meta-analysis. *J. Neurol.*
1432 *Neurosurg. Psychiatry* **75**, 962–965 (2004).
- 1433 48. Zabetian, C. P. *et al.* Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson’s
1434 disease. *Ann. Neurol.* **62**, 137–144 (2007).
- 1435 49. Sánchez-Juan, P. *et al.* The MAPT H1 Haplotype Is a Risk Factor for Alzheimer’s Disease in APOE ε4
1436 Non-carriers. *Front. Aging Neurosci.* **11**, 327 (2019).
- 1437 50. Jovanovic, M. *et al.* Immunogenetics. Dynamic profiling of the protein life cycle in response to pathogens.
1438 *Science* **347**, 1259038 (2015).
- 1439 51. Emani, P. S. *et al.* Single-cell genomics and regulatory networks for 388 human brains. *Science* **384**,
1440 eadi5199 (2024).
- 1441 52. Yang, A. C. *et al.* A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk. *Nature* **603**,

- 1442 885–892 (2022).
- 1443 53. Hoffman, G. E. *et al.* Efficient differential expression analysis of large-scale single cell transcriptomics data
1444 using dreamlet. *bioRxiv* (2023) doi:10.1101/2023.03.17.533005.
- 1445 54. Boyle, E. A., Li, Y. I. & Pritchard, J. K. An Expanded View of Complex Traits: From Polygenic to
1446 Omnigenic. *Cell* **169**, 1177–1186 (2017).
- 1447 55. Lyketsos, C. G. *et al.* Prevalence of neuropsychiatric symptoms in dementia and mild cognitive
1448 impairment: results from the cardiovascular health study. *JAMA* **288**, 1475–1483 (2002).
- 1449 56. Bhattacharjee, A. *et al.* Cell type-specific transcriptional programs in mouse prefrontal cortex during
1450 adolescence and addiction. *Nat. Commun.* **10**, 4169 (2019).
- 1451 57. Green, G. S. *et al.* Cellular dynamics across aged human brains uncover a multicellular cascade leading
1452 to Alzheimer's disease. *bioRxiv* 2023.03.07.531493 (2023) doi:10.1101/2023.03.07.531493.
- 1453 58. Lee, D. *et al.* Plasticity of Human Microglia and Brain Perivascular Macrophages in Aging and Alzheimer's
1454 Disease. *medRxiv* 2023.10.25.23297558 (2023) doi:10.1101/2023.10.25.23297558.
- 1455 59. Roussos, P. *et al.* Alzheimer's disease transcriptional landscape in ex-vivo human microglia. *Res Sq*
1456 (2024) doi:10.21203/rs.3.rs-3851590/v1.
- 1457 60. Kitano, H. Computational systems biology. *Nature* **420**, 206–210 (2002).
- 1458 61. Bhembre, N., Bonthron, C. & Opazo, P. Synaptic Compensatory Plasticity in Alzheimer's Disease. *J.*
1459 *Neurosci.* **43**, 6833–6840 (2023).
- 1460 62. Hernández-Ortega, K., Garcia-Esparcia, P., Gil, L., Lucas, J. J. & Ferrer, I. Altered Machinery of Protein
1461 Synthesis in Alzheimer's: From the Nucleolus to the Ribosome. *Brain Pathol.* **26**, 593–605 (2016).
- 1462 63. Moreira, P. I., Carvalho, C., Zhu, X., Smith, M. A. & Perry, G. Mitochondrial dysfunction is a trigger of
1463 Alzheimer's disease pathophysiology. *Biochim. Biophys. Acta* **1802**, 2–10 (2010).
- 1464 64. Lee, J.-H. *et al.* Faulty autolysosome acidification in Alzheimer's disease mouse models induces
1465 autophagic build-up of A β in neurons, yielding senile plaques. *Nat. Neurosci.* **25**, 688–701 (2022).
- 1466 65. Butterfield, D. A. & Halliwell, B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer
1467 disease. *Nat. Rev. Neurosci.* **20**, 148–160 (2019).
- 1468 66. Mallach, A. *et al.* Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease

- 1469 mouse model, as revealed by spatial transcriptomics. *Cell Rep.* **43**, 114216 (2024).
- 1470 67. Marsh, S. E. *et al.* The adaptive immune system restrains Alzheimer's disease pathogenesis by
1471 modulating microglial function. *Proceedings of the National Academy of Sciences* **113**, E1316–E1325
1472 (2016).
- 1473 68. Grayson, J. M. *et al.* T cell exhaustion is associated with cognitive status and amyloid accumulation in
1474 Alzheimer's disease. *Sci. Rep.* **13**, 15779 (2023).
- 1475 69. Su, W. *et al.* CXCR6 orchestrates brain CD8⁺ T cell residency and limits mouse Alzheimer's disease
1476 pathology. *Nat. Immunol.* **24**, 1735–1747 (2023).
- 1477 70. Haney, M. S. *et al.* APOE4/4 is linked to damaging lipid droplets in Alzheimer's disease microglia. *Nature*
1478 **628**, 154–161 (2024).
- 1479 71. Marschallinger, J. *et al.* Lipid-droplet-accumulating microglia represent a dysfunctional and
1480 proinflammatory state in the aging brain. *Nat. Neurosci.* **23**, 194–208 (2020).
- 1481 72. Claes, C. *et al.* Plaque-associated human microglia accumulate lipid droplets in a chimeric model of
1482 Alzheimer's disease. *Mol. Neurodegener.* **16**, 50 (2021).
- 1483 73. Lee, D. *et al.* Plasticity of human microglia and brain perivascular macrophages in aging and Alzheimer's
1484 disease. *bioRxiv* (2023) doi:10.1101/2023.10.25.23297558.
- 1485 74. Zhu, J., He, F., Hu, S. & Yu, J. On the nature of human housekeeping genes. *Trends Genet.* **24**, 481–484
1486 (2008).
- 1487 75. Eisenberg, E. & Levanon, E. Y. Human housekeeping genes, revisited. *Trends Genet.* **29**, 569–574
1488 (2013).
- 1489 76. Jorstad, N. L. *et al.* Comparative transcriptomics reveals human-specific cortical features. *Science* **382**,
1490 eade9516 (2023).
- 1491 77. Louveau, A. *et al.* Structural and functional features of central nervous system lymphatic vessels. *Nature*
1492 **523**, 337–341 (2015).
- 1493 78. Ahn, J. H. *et al.* Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. *Nature* **572**, 62–66
1494 (2019).
- 1495 79. Li, X. *et al.* Meningeal lymphatic vessels mediate neurotropic viral drainage from the central nervous

- 1496 system. *Nat. Neurosci.* **25**, 577–587 (2022).
- 1497 80. Fitzpatrick, Z. *et al.* Venous-plexus-associated lymphoid hubs support meningeal humoral immunity.
1498 *Nature* **628**, 612–619 (2024).
- 1499 81. Da Mesquita, S. *et al.* Meningeal lymphatics affect microglia responses and anti-A β immunotherapy.
1500 *Nature* **593**, 255–260 (2021).
- 1501 82. Louveau, A. *et al.* CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic
1502 vasculature. *Nat. Neurosci.* **21**, 1380–1391 (2018).
- 1503 83. Da Mesquita, S., Fu, Z. & Kipnis, J. The Meningeal Lymphatic System: A New Player in Neurophysiology.
1504 *Neuron* **100**, 375–388 (2018).
- 1505 84. Da Mesquita, S. *et al.* Functional aspects of meningeal lymphatics in ageing and Alzheimer’s disease.
1506 *Nature* **560**, 185–191 (2018).
- 1507 85. Long, J. M. & Holtzman, D. M. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
1508 *Cell* **179**, 312–339 (2019).
- 1509 86. Ryder, B. D., Wydorski, P. M., Hou, Z. & Joachimiak, L. A. Chaperoning shape-shifting tau in disease.
1510 *Trends Biochem. Sci.* **47**, 301–313 (2022).
- 1511 87. Mok, S.-A. *et al.* Mapping interactions with the chaperone network reveals factors that protect against tau
1512 aggregation. *Nat. Struct. Mol. Biol.* **25**, 384–393 (2018).
- 1513 88. Koren, J., 3rd *et al.* Chaperone signalling complexes in Alzheimer’s disease. *J. Cell. Mol. Med.* **13**, 619–
1514 630 (2009).
- 1515 89. Saha, I. *et al.* The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a
1516 cellular system. *Nat. Commun.* **14**, 560 (2023).
- 1517 90. Brigas, H. C. *et al.* IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer’s
1518 disease. *Cell Rep.* **36**, 109574 (2021).
- 1519 91. Rosenzweig, N. *et al.* Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment
1520 in Alzheimer’s disease. *Nat. Med.* (2024) doi:10.1038/s41591-024-03122-3.
- 1521 92. Cipollini, V., Anrather, J., Orzi, F. & Iadecola, C. Th17 and Cognitive Impairment: Possible Mechanisms of
1522 Action. *Front. Neuroanat.* **13**, 95 (2019).


- 1523 93. Criado-Marrero, M. *et al.* Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged
1524 wild-type mice. *Acta Neuropathol Commun* **9**, 65 (2021).
- 1525 94. Gorantla, N. V. & Chinnathambi, S. Tau Protein Squired by Molecular Chaperones During Alzheimer's
1526 Disease. *J. Mol. Neurosci.* **66**, 356–368 (2018).
- 1527 95. Galea, I. The blood-brain barrier in systemic infection and inflammation. *Cell. Mol. Immunol.* **18**, 2489–
1528 2501 (2021).
- 1529 96. Bennett, D. A. *et al.* Religious Orders Study and Rush Memory and Aging Project. *J. Alzheimers. Dis.* **64**,
1530 S161–S189 (2018).
- 1531 97. Marquez, D. X. *et al.* Representation of Older Latinxs in Cohort Studies at the Rush Alzheimer's Disease
1532 Center. *Neuroepidemiology* **54**, 404–418 (2020).
- 1533 98. Mirra, S. S. *et al.* The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II.
1534 Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* **41**, 479–486
1535 (1991).
- 1536 99. Bennett, D. A. *et al.* Neuropathology of older persons without cognitive impairment from two community-
1537 based studies. *Neurology* **66**, 1837–1844 (2006).
- 1538 100. Bennett, D. A. *et al.* Natural history of mild cognitive impairment in older persons. *Neurology* **59**, 198–205
1539 (2002).
- 1540 101. Bennett, D. A. *et al.* Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-
1541 based cohort studies compared to standard practice in a clinic-based cohort study. *Neuroepidemiology* **27**,
1542 169–176 (2006).
- 1543 102. Fullard, J. F. *et al.* Population-scale cross-disorder atlas of the human prefrontal cortex at single-cell
1544 resolution.
- 1545 103. Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *J. Mach. Learn. Res.* **12**, 2825–2830 (2011).
- 1546 104. Borrell, L. N. *et al.* Race and Genetic Ancestry in Medicine - A Time for Reckoning with Racism. *N. Engl.*
1547 *J. Med.* **384**, 474–480 (2021).
- 1548 105. Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol.* **82**,
1549 239–259 (1991).

- 1550 106. Braak, H., Alafuzoff, I., Arzberger, T., Kretschmar, H. & Del Tredici, K. Staging of Alzheimer disease-
1551 associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol.*
1552 **112**, 389–404 (2006).
- 1553 107. Braak, H., Thal, D. R., Ghebremedhin, E. & Del Tredici, K. Stages of the pathologic process in Alzheimer
1554 disease: age categories from 1 to 100 years. *J. Neuropathol. Exp. Neurol.* **70**, 960–969 (2011).
- 1555 108. Stoeckius, M. *et al.* Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for
1556 single cell genomics. *Genome Biol.* **19**, 224 (2018).
- 1557 109. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21 (2013).
- 1558 110. Kaminow, B., Yunusov, D. & Dobin, A. STARsolo: accurate, fast and versatile mapping/quantification of
1559 single-cell and single-nucleus RNA-seq data. *bioRxiv* 2021.05.05.442755 (2021)
1560 doi:10.1101/2021.05.05.442755.
- 1561 111. Huang, Y., McCarthy, D. J. & Stegle, O. Vireo: Bayesian demultiplexing of pooled single-cell RNA-seq
1562 data without genotype reference. *Genome Biol.* **20**, 273 (2019).
- 1563 112. Li, B. *et al.* Cumulus provides cloud-based data analysis for large-scale single-cell and single-nucleus
1564 RNA-seq. *Nat. Methods* **17**, 793–798 (2020).
- 1565 113. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis.
1566 *Genome Biol.* **19**, 15 (2018).
- 1567 114. Wolock, S. L., Lopez, R. & Klein, A. M. Scrublet: Computational Identification of Cell Doublets in Single-
1568 Cell Transcriptomic Data. *Cell Syst* **8**, 281–291.e9 (2019).
- 1569 115. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat. Methods*
1570 **16**, 1289–1296 (2019).
- 1571 116. Zheng, G. X. Y. *et al.* Massively parallel digital transcriptional profiling of single cells. *Nat. Commun.* **8**,
1572 14049 (2017).
- 1573 117. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected
1574 communities. *Sci. Rep.* **9**, 5233 (2019).
- 1575 118. McInnes, L., Healy, J. & Melville, J. UMAP: Uniform Manifold Approximation and Projection for Dimension
1576 Reduction. *arXiv [stat.ML]* (2018).



- 1577 119. Xu, C. *et al.* Probabilistic harmonization and annotation of single-cell transcriptomics data with deep
1578 generative models. *Mol. Syst. Biol.* **17**, e9620 (2021).
- 1579 120. Gayoso, A. *et al.* A Python library for probabilistic analysis of single-cell omics data. *Nat. Biotechnol.* **40**,
1580 163–166 (2022).
- 1581 121. Virshup, I. *et al.* The scverse project provides a computational ecosystem for single-cell omics data
1582 analysis. *Nat. Biotechnol.* **41**, 604–606 (2023).
- 1583 122. Kosoy, R. *et al.* Genetics of the human microglia regulome refines Alzheimer’s disease risk loci. *Nat.*
1584 *Genet.* **54**, 1145–1154 (2022).
- 1585 123. Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**,
1586 290–299 (2021).
- 1587 124. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies. *Bioinformatics* **26**,
1588 2867–2873 (2010).
- 1589 125. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation. *Nature* **526**, 68–
1590 74 (2015).
- 1591 126. Danecek, P. *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**, (2021).
- 1592 127. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.
1593 *Gigascience* **4**, 7 (2015).
- 1594 128. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C. A. & Smoller, J. W. Polygenic prediction via Bayesian regression
1595 and continuous shrinkage priors. *Nat. Commun.* **10**, 1776 (2019).
- 1596 129. Bowles, K. R. *et al.* 17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are
1597 associated with LRRC37A/2 expression in astrocytes. *Mol. Neurodegener.* **17**, 48 (2022).
- 1598 130. Browning, B. L., Tian, X., Zhou, Y. & Browning, S. R. Fast two-stage phasing of large-scale sequence
1599 data. *Am. J. Hum. Genet.* **108**, 1880–1890 (2021).
- 1600 131. Hoffman, G. E. & Roussos, P. *Count Ratio Uncertainty Modeling Based Linear Regression.* (2024).
1601 doi:10.5281/zenodo.12752107.
- 1602 132. Lähnemann, D. *et al.* Eleven grand challenges in single-cell data science. *Genome Biol.* **21**, 31 (2020).
- 1603 133. Crowell, H. L. *et al.* muscat detects subpopulation-specific state transitions from multi-sample multi-




- 1604 condition single-cell transcriptomics data. *Nat. Commun.* **11**, 6077 (2020).
- 1605 134. Squair, J. W. *et al.* Confronting false discoveries in single-cell differential expression. *Nat. Commun.* **12**,
1606 5692 (2021).
- 1607 135. Zimmerman, K. D., Espeland, M. A. & Langefeld, C. D. A practical solution to pseudoreplication bias in
1608 single-cell studies. *Nat. Commun.* **12**, 738 (2021).
- 1609 136. Murphy, A. E., Fancy, N. N. & Skene, N. G. Avoiding false discoveries: Revisiting an Alzheimer's disease
1610 snRNA-Seq dataset. *bioRxiv* 2023.04.01.535040 (2023) doi:10.1101/2023.04.01.535040.
- 1611 137. Hoffman, G. E. & Roussos, P. Dream: powerful differential expression analysis for repeated measures
1612 designs. *Bioinformatics* **37**, 192–201 (2021).
- 1613 138. Wu, D. & Smyth, G. K. Camera: a competitive gene set test accounting for inter-gene correlation. *Nucleic
1614 Acids Res.* **40**, e133 (2012).
- 1615 139. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-
1616 wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
- 1617 140. Chia, R. *et al.* Genome sequencing analysis identifies new loci associated with Lewy body dementia and
1618 provides insights into its genetic architecture. *Nat. Genet.* **53**, 294–303 (2021).
- 1619 141. Ferrari, R. *et al.* Frontotemporal dementia and its subtypes: a genome-wide association study. *Lancet
1620 Neurol.* **13**, 686–699 (2014).
- 1621 142. Trapnell, C. *et al.* The dynamics and regulators of cell fate decisions are revealed by pseudotemporal
1622 ordering of single cells. *Nat. Biotechnol.* **32**, 381–386 (2014).
- 1623 143. Bendall, S. C. *et al.* Single-cell trajectory detection uncovers progression and regulatory coordination in
1624 human B cell development. *Cell* **157**, 714–725 (2014).
- 1625 144. Lopez, R., Regier, J., Cole, M. B., Jordan, M. I. & Yosef, N. Deep generative modeling for single-cell
1626 transcriptomics. *Nat. Methods* **15**, 1053–1058 (2018).
- 1627 145. Loshchilov, I. & Hutter, F. Decoupled Weight Decay Regularization. *arXiv [cs.LG]* (2017).
- 1628 146. Idrissi, B. Y., Arjovsky, M., Pezeshki, M. & Lopez-Paz, D. Simple data balancing achieves competitive
1629 worst-group-accuracy. *arXiv [cs.LG]* (2021).
- 1630 147. Wang, J. Z., Du, Z., Payattakool, R., Yu, P. S. & Chen, C.-F. A new method to measure the semantic








1631 similarity of GO terms. *Bioinformatics* **23**, 1274–1281 (2007).



AD
concordance








All Subdivisions


Neurons Only

1	0.98	0.18	0.98	0.98	0.98	0.98	0.98	0.98
0.98	1	0.25	0.94	0.92	0.96	0.97	0.95	0.95
0.18	0.25	1	0.74	0.78	0.74	0.78	0.77	0.77
0.98	0.94	0.74	1	0.94	0.91	0.94	0.94	0.94
0.92	0.92	0.78	0.94	1	0.77	0.90	0.90	0.90
0.98	0.96	0.74	0.91	0.77	1	0.97	0.9	0.9
0.98	0.97	0.78	0.94	0.90	0.97	1	0.97	0.97
0.95	0.95	0.77	0.94	0.90	0.9	0.97	1	0.97
0.95	0.95	0.77	0.94	0.90	0.97	0.97	0.97	1


NPD NDD












1000




NPD NDD














EN_L1_2_3_4_5_6_7_8_9_10_11_12_13_14_15_16_17_18_19_20_21_22_23_24_25_26_27_28_29_30_31_32_33_34_35_36_37_38_39_40_41_42_43_44_45_46_47_48_49_50_51_52_53_54_55_56_57_58_59_60_61_62_63_64_65_66_67_68_69_70_71_72_73_74_75_76_77_78_79_80_81_82_83_84_85_86_87_88_89_90_91_92_93_94_95_96_97_98_99_100









n_cells




UMI counts per sample




Gene counts per sample




2924 samples
















1494 donors





n_muscle



















Absolute logFC by Assay and Trait











Standard training




Equal sampling










a



b

